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Abstract 
 
Paclitaxel (PTX) is one of the leading chemotherapy drugs available for various solid tumor 
cancers and is most commonly administered systemically in a solution consisting of dehydrated 
alcohol and Cremophor EL. This project investigated the potential for a Taxus suspension culture 
derived local delivery system of PTX. For this purpose, increased cell-associated PTX 
accumulation, DNA removal, and release kinetics were investigated. PTX was retained throughout 
a piloted decellularization process at an average of 0.68 mg/L with greater than 80% DNA 
removal. The decellularized biomass allowed for almost complete drug release within 72 hours of 
suspension in 4 % bovine serum albumin solution. Initial release rate could be sustained when 
encapsulated in calcium alginate microbeads, suggesting this to be a feasible approach for PTX 
delivery. Moving forward, increasing the amount of PTX produced by Taxus culture through 
alternative elicitation methods and maximizing the PTX retained through processing is imperative 
to the feasibility of a cell culture-based drug delivery system. 
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Chapter 1: Introduction 
Cancer is one of the most prominent diseases in the world. The International Agency for 
Research on Cancer estimates there will be 18.1 million new cancer cases in 2018 and 9.6 million 
cancer deaths worldwide Bray, Ferlay [1]. Advancing treatments for cancer patients drives a large 
portion of the health field. In 2017, the NIH put $6.3 billion of its $33.1 billion budget towards 
cancer research [2]. Along with the development of new treatment options, traditional treatments 
are continuously being improved. In particular, chemotherapy, one of the three main treatment 
methods for solid tumors (along with surgery and radiation therapy), results in many negative side 
effects and is therefore continually being refined [3]. Paclitaxel (PTX), one of the most effective 
chemotherapy drugs has been a target for such advancements [4]. 
Currently, the majority of PTX is synthesized from a precursor molecule, 10-
deacetylbaccatin III, extracted from the renewable twigs and leaves of yew trees (Taxus), a natural 
source of PTX [5]. Taxus suspension cell culture has the potential to be an alternative source of 
the drug. Methods to increase the production of PTX in these cultures have been studied [6]. At 
present, once PTX is synthesized and purified, harsh solvents are necessary to systemically deliver 
the hydrophobic drug to the patient [7]. Alternative delivery systems, such as liposome 
encapsulation and impregnation in solid materials for direct (local) delivery are under development 
in order to circumvent the need for these solvents [8, 9].  
Investigations have been performed on the use of whole-plant treatments which can exploit 
synergistic effects of the naturally produced drug and other compounds present in the plant 
material [10]. Whole-plant treatments do, however, have design challenges that differ from the 
traditional drug-only approach. The use of total Taxus cell culture is potentially compatible with 
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several direct drug delivery techniques, such as injectable gels, liposomes, and scaffolds. Utilizing 
total cell culture as a direct delivery system may reduce or eliminate dangerous side effects 
associated with current delivery methods, bypass the need for purification from culture, which is 
very complex, and reduce the total amount of drug required compared to systemic delivery. 
Additionally, the cultures’ ability to produce assorted taxanes and other specialized metabolites 
could change the efficacy of the drug through synergistic effects. 
This Major Qualifying Project studied processed Taxus suspension culture as part of a 
delivery system for local PTX delivery. It piloted the decellularization process of Taxus and 
examined the retention of PTX and other specialized metabolites while quantifying DNA removal. 
This study explores the potential of a total Taxus cell culture derived drug delivery system through 
the investigation of three aims:  
Aim 1: Identify strategies to increase the concentration of cell-associated PTX in vitro to 
prepare the plant cell for use as a drug delivery system.  
Aim 2: Optimize the decellularization of plant cell culture to develop a biomaterial 
capable of delivering PTX. 
Aim 3: Quantify the feasibility of the biomaterial through evaluation of its release profile 
in protein-saturated liquid both alone and encapsulated in a protective hydrogel. 
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Chapter 2: Background 
2.1. Paclitaxel  
2.1.1 History 
PTX is an anti-tumor drug discovered through the plant and natural products screening 
program conducted by the National Cancer Institute (NCI) and United States Department of 
Agriculture between 1960 and 1981 [11]. PTX, trademarked as Taxol®, was first isolated from 
the bark of the Pacific Yew tree, T. brevifolia, and moved into the NCI drug development program 
[12]. Today, PTX, a highly cytotoxic compound, remains a popular chemotherapy agent, used in 
the treatment of breast, ovarian, lung, and prostate cancers and other solid tumor cancers [13]. In 
addition to the treatment of cancers, PTX has been studied to treat other health afflictions including 
psoriasis [14] and to minimize restenosis after coronary stenting [15]. Overall, PTX acts as a non-
proliferative and immunosuppressive agent with many applications in the medical field.  
2.1.2 Biosynthesis, Structure, and Mechanism  
Biosynthesis and Structure 
PTX is a member of the taxane family, a class of diterpenes. Like all taxanes, it contains a 
taxadiene three-ring core [16]. Currently, its biosynthetic pathway is not completely understood, 
though it is predicted to contain nineteen steps, many of which have yet to be characterized [4]. 
Figure 1 depicts the steps of the currently-known biosynthetic pathway of PTX in Taxus. Several 
notable compounds along the pathway are geranylgeranyl diphosphate, an important precursor for 
all diterpenoids, taxadiene, the foundation of all taxanes that provides the characteristic three-ring 
base structure, as well as baccatin III and 10-deacyclbaccatin III which are important precursors 
used for semi-synthesis of PTX [17, 18]. 
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Figure 1:  The hypothesized biosynthetic pathway of PTX within Taxus. The blue box 
shows the synthesis of the precursor BAPT while the yellow box shows another path which 
Taxadien-5α-ol can take which does not lead to PTX production. Note that there are a 
number of uncharacterized steps between the taxadiene alterations of the synthesis and the 
creation of 2-debenzoyltaxane. Adapted from [17]. 
 
Other Taxanes 
Taxanes other than PTX as well as PTX precursors have shown significant bioactivity 
making them compounds of interest [19]. Many of these taxanes produced in Taxus cell culture 
have yet to be isolated, identified, or tested for activity due to the low quantities at which they 
naturally accumulate [19]. It is important to note that these taxanes of interest and the PTX 
precursors are produced both naturally by whole plants as well as in plant cell culture.  
Docetaxel, a synthetic analog of PTX, is a taxane that boasts higher aqueous solubility and 
therefore higher bioavailability [20]. Cabazitaxel, a commercially available semi-synthetic taxoid 
derivative, is used for the treatment of prostate cancer. These synthesized alternatives retain the 
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base mechanism of which PTX is most effective and show promising results as alternative 
treatments to the natural compound [21, 22]. It is important to note that these analogs are by 
definition synthetic and therefore are not produced naturally via Taxus culture or otherwise. These 
compounds’ structures as well as PTX are pictured in Figure 2 [21]. 
 
Figure 2: The relative structures of paclitaxel, docetaxel, and cabazitaxel. Note the 
consistency of the basic three ring structure and the differences in the ‘tail’ between 
paclitaxel and the two semi-synthetics.  
 
Mechanism of Action 
PTX interrupts cell function by altering microtubule stability within cancer cells. Through 
excessive promotion of tubulin polymerization, PTX treatment results in microtubules that are 
overly stable and therefore dysfunctional [4]. This stability directly interferes with the ability of a 
cell to successfully form the mitotic spindle during division, inevitably inducing cell death [23]. It 
is suggested that PTX produces stable microtubules due to increased dimer contacts of axial 
tubulin and a rearrangement of density in a-tubulin subunits [24]. As a result of its mechanism of 
action, PTX has an intensified effect on cells that are rapidly proliferating, such as cancer cells. 
Additionally, studies have investigated other mechanisms through which PTX may affect 
cell function. One study found that in the presence of the P-53 tumor suppressor gene, PTX can 
stimulate the lipopolysaccharide signaling pathway in murine macrophages which can cause the 
secretion of cytokines interleukin 1b and tumor necrosis factor a, the latter of which can induce 
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apoptosis [25]. This mechanism is independent of microtubule production and may be due to an 
increase in the activity of NADPH oxidase, which increases the generation of reactive oxygen 
species which may participate in P53-independent apoptosis [23]. In small doses PTX has been 
shown to stimulate the immune system partially due to its ability to enhance the activation of 
human dendritic cells independent of TLR4 binding [26]. Overall, PTX is effective in decreasing 
tumor viability because of its ability to influence various cells processes leading to cell death. 
2.1.3 Production  
The drug PTX was originally isolated from extracts from the bark of yew trees. Extraction 
of PTX uses an organic solvent, typically an alcohol, to obtain a crude product which is then put 
through several purification steps to arrive at an applicable concentration of the drug (typically 6 
mg/ml) [27]. Some common purification procedures include filtration, n-hexane extraction (which 
favors PTX), and various forms of liquid chromatography [28]. However, this process is not 
practical for large-scale production for several reasons. Namely, the amounts of PTX produced 
naturally are too low for natural harvest to be useful with nearly 3,000 full-grown trees required to 
make one kilogram of the drug [29]. This amounts to approximately 8 adult yew trees to treat one 
cancer patient [30]. Considering that the harvesting process requires the complete processing and 
sacrifice of the tree, the number of trees, space, and time needed to keep up with today’s demands 
would be astronomical, and therefore not feasible. Additionally, the accumulated concentrations 
of the drug in the natural plant has been shown to vary seasonally, further complicating the ability 
for consistent production [31]. 
Due to the difficulties associated with the use of extraction methods for large-scale 
production of PTX, numerous efforts have been made to develop alternatives that are more 
sustainable and consistent. Various pathways for the complete synthesis of PTX were first 
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published in 1994. These groups included the Houlton group, which designed a linear synthesis 
pathway with the precursor patchoulol [32], and the Nicolaou group who started from mucic acid 
[33]. Despite their success, these processes were outshined by a semisynthetic process which uses 
the natural product 10-deacetylbaccatin III which accumulates in the yew at a much higher rate 
than PTX. The natural product is extracted, protected, and then reacted with 3R,4S-N-benzoyl-3-
(1-ethoxy-ethoxy)-4-phenyl-2-azetidinone which adds the requisite tail [18]. 
10-Deacetylbaccatin III can be isolated from the twigs and leaves of the yew (both more 
renewable sources) in quantities sufficient for processing, decreasing the impact of extraction on 
the trees themselves [18]. This process, trademarked by Bristol-Myer Squib, is the primary source 
of the commercialized form of PTX (Taxol®), utilized today. This semi-synthesis is favorable to 
complete synthesis for its decreased number of reaction steps and reduced environmental impact 
as compared to a purely natural extraction [18].  
2.1.4 Taxus Suspension Cultures for Paclitaxel Production 
The development of suspension cultures of Taxus for use as production systems stems from 
the challenges of the other available methods of production. By providing opportunity for 
sustained production, higher yields, and more efficient processing, plant cell culture is a promising 
production avenue for plant derived metabolites that are otherwise difficult to procure [6]. The 
process begins with the needles of the Taxus brevefolia which are sterilized by suspending in a 1% 
aqueous hypochlorite solution for ten minutes [34]. Next, the needles are removed from the 
solution washed with sterile water, then cut into small pieces and plated onto solid media [34]. 
Every four weeks, the calli are transferred to new solid media until there is enough callus mass to 
create a liquid suspension culture [34]. To create a liquid suspension, approximately 5 grams of 
friable calli is disaggregated using a spatula and transferred into liquid media. Then, a pipette is 
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used to shear calli into smaller aggregates [34]. Taxus suspension cultures have a doubling rate of 
about 4 to 8 days [35] so a 5 grams of calli takes significant time to accumulate. Liquid cultures 
are transferred every 14 days. This process is long and requires exceptional sterility due to the 
culture's high susceptibility to fungal and bacterial contamination [34].  
The method of liquid suspension production is notably not available for synthetic 
alternatives to PTX, presenting an opportunity unique to the natural drug. Plant cultures also 
produce an assortment of other natural products associated with plant cell function including 
proteins, a variety of specialized metabolites (formerly secondary metabolites), and other taxanes; 
all of which can be impacted by the culture’s response to stimuli. In Taxus, these metabolites 
primarily include phenolics, flavonoids, and other taxanes. These cell cultures can display a large 
degree of heterogeneity particularly in size, shape, and metabolic function which can cause wide 
variation in the production of PTX in cultures [35, 36].  
2.1.5 Delivery of Paclitaxel 
PTX’s natural hydrophobicity requires it be bound or dissolved in specialized solvents 
before being used as a therapeutic. There are two main forms in which PTX is currently used for 
chemotherapeutic applications. The first is the traditional solvent-based variety. In this form, PTX 
is administered using Cremophor EL, a non-ionic surfactant mainly composed of oxylated 
triglycerides of ricinoleic acid soluable in water, and dehydrated ethanol as a drug delivery 
formulation [37, 38]. Treatment with this formulation often results in toxic side effects, due not 
only to PTX itself, but also the associated solvents [37]. The second form, albumin bound PTX 
(nab-paclitaxel), has recently gained popularity, as the protein bound PTX has greater solubility in 
water and higher biocompatibility, thus reducing toxicity and making it an atrractive alternative. 
Due to the reduced toxicity increased dosages of PTX can be achieved resulting in more effective 
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treatments and higher survival rates. In a 2012 study, nab-paclitaxel nanoparticle formulation was 
shown to significantly increase the proportion of early stage breast cancer patients achieving a 
pathologically complete response rate [39].  
The development of alternative PTX delivery methods is currently a research topic of 
increasing interest. Current studies have investigated the use of emulsions, co-solvents or 
surfactants to increase the solubility of PTX [40]. The development of prodrugs, or inactive 
derivatives of parent drugs that convert into the bioactive compound in the body also show 
promise. Significant research has been done on prodrugs developed with an addition of ester 
groups to the C-2’ and C-7’ hydroxyl groups as well as additions of carbonates and carbamates to 
the C-2’ group [41]. While these prodrugs create compounds with the ability to dissolve in water, 
a current challenge in their development is the tuning of their in vivo stability so they can convert 
to the parent drug readily [41]. Other studies have looked at the delivery of PTX encapsulated in 
delivery vessels such as liposomes, nanoparticles, or thin films [40]. 
 
2.2 Drug Delivery Systems 
A multitude of drug delivery systems (DDSs) are utilized in everyday life: from 
intramuscular flu shot vaccinations to topical antibacterial ointment applied to abrasions. 
Successful drug delivery systems must be designed with the targeted system of interest in mind 
and effective at releasing the drug in the desired concentration at the desired rate. Systems vary 
vastly in design: some as simple as a solvent for the drug to be delivered systemically, while others 
use specialized materials to control the release of a drug over time to target locations.  
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Drug delivery systems can be classified into two broad categories, systemic and local, both 
of which can be augmented to target specific cells within the body. In systemic delivery, the drug 
is transported throughout the body through the circulatory system after being administered in 
various methods some of which include intravenous, oral, and pulmonary delivery [42]. 
2.2.1 Local Drug Delivery Systems 
Local DDS, drugs are delivered by placing them physically in, on, or near the target 
treatment site. Examples of these includes solids, wafers, particles, powders, pastes foams, gels, 
membranes, and films [8, 9]. One of the many benefits of direct delivery systems is that they do 
not require the drug to travel through the entire circulatory system, this allows for the use of smaller 
concentrations of the drug because there are fewer opportunities for degradation or metabolism 
before the drug reaches the target area. Additionally, direct delivery avoids the distribution of the 
drug to other sites where it may potentially have harmful effects. A concern of direct delivery is 
the necessity to be physically placed on or near the target site which can be difficult or even 
impossible depending on site accessibility. One example of an effective direct delivery system 
available today is the Gliadel® Wafer, a carmustine-loaded polymer wafer made by MGI Pharma 
used to treat malignant glioma, a common type of brain tumor in adults [43].  
Local delivery methods call for rate-controlled release of the drug to the target site 
governed by principles of mass transfer. Factors such as the concentration of a drug in a delivery 
system and temperature can influence release rate [44]. Delivery methods may also incorporate 
physical targeting methods, such as pH dependent or enzymatic release [10].  
A common problem with direct delivery systems is the formation of a fibrous capsule 
around the DDS, hindering transfer of drug to the target [45], but fibrous capsule development can 
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be controlled with anti-inflammatories such as dexamethasone [46]. Transfer of cancer drugs to 
tumors has been demonstrated to be aided by the implantation of the delivery system inside the 
tumor [45]. One study examined implantation methods of doxorubicin loaded polymer millirods 
in tumorous rat livers [47]. It was found that ablation, or breaking, of tissue prior to insertion 
resulted in a maximum concentration of drug in tumor tissue of approximately four times than that 
of non-ablated tissue [47]. Unfortunately, ablated tissue can develop fibrous capsule over time 
which has been shown to decrease drug transfer into tumor cells, but treatment of ablated tissue 
with an anti-inflammatory can reduce fibrous capsule development [47]. Additionally, tumor 
reoccurrence at the boundaries of ablation is a common issue [48]. As PTX has anti-inflammatory 
properties, fibrous capsule formation may be inhibited in the case of a PTX loaded implantation 
device [8]. 
Another example of local delivery is the incorporation of PTX and polyethylene glycol 
(PEG) into thin poly(lactic acid-co-glycolic acid) (PGLA) films [49]. The rate of PTX release 
correlates to the crystallinity and its affiliation with the PEG present in the film due to phase 
separation of crystalline PEG, creating pores that allow for diffusion of PTX from the system. PEG 
higher in crystallinity resulted in faster release of PTX but was also attributed with lower tensile 
strength of the film after phase separation [49].    
Local drug delivery systems are not without challenges, and may, for example, face 
rejection from the body and inadequate drug diffusion and bioavailability. However, they offer an 
alternate method for drug delivery that could significantly increase the efficacy of a drug if 
designed with these issues in mind. 
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2.2.2 Properties of Successful Local Drug Delivery Systems 
In solid delivery systems, physical integrity and flexibility are important factors in 
successful designs. Scaffolds are often used as a supportive structure which allows solid delivery 
systems to maintain their form and functionality. These scaffolds can be composed of various 
materials including electro-spun mats, lyophilized sponges, hydrogels, and collagen [8, 50]. 
Collagen and decellularized skin (human, porcupine, or bovine) are particularly appealing scaffold 
materials due their natural and similar components to the tissues they interact with when implanted 
as well as their strength and flexibility increasing their biocompatibility [8, 50]. With these 
structural properties in mind various solid drug delivery systems are currently being investigated 
for their use in the treatment of various ailments. This research includes the investigation of films, 
wafers, stents, and thermogels (a polymer solution which forms a gel at a specific concentration 
and temperature).  
Silk films have been a potential candidate for the delivery and sustained release of 
anticancer agent doxorubicin as well as platinum-based drugs [51, 52]. Bilayer silk films can 
provide time dependent delivery to target cells through the exploitation of physical properties, such 
as hydrophobicity and charge [53]. In comparison, homogeneously-made (constant concentration 
of drug throughout material) Gliadel® wafers utilize a copolymer matrix made of 1,3-bis(p-
carboxyphenoxy) propane and sebacic acid in a 20:80 molar ratio to deliver carmustine, an 
anticancer agent, directly to tumor cells [54]. Although wafers and films stay in place and provide 
localized treatment, they generally tend to develop a buildup of tissue around them (fibrous capsule 
formation), which can hinder drug delivery due to the additional physical barrier [45]. 
For the development of PTX eluting stents, various polymers have been studied. One stent, 
TAXUSTM Express2 ® (Boston Scientific, Marlborough, MA) uses the polymer translate 
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[poly(styrene-b-isobutylene-b-styrene)] as an inactive carrier of PTX [55]. Unfortunately, this 
polymer has appeared to result in inflammation of surrounding tissue and potential blood clotting 
[7]. An alternative polymer, poly(ethylene carbonate) was studied separately as a PTX eluting stent 
coating. This PTX coating is released in the presence of inflammation of the blood vessel when 
the stent is under stress in order to treat the inflammation and allow the stent to continue to function 
properly [7].   
The use of low-dose PTX-loaded thermogels on the surface of implantable medical devices 
has been studied to reduce the formation of fibrous capsules around silicone implants and avoid 
interruption of drug delivery over time [56]. PTX was of interest in these studies due to its capacity 
to inhibit collagen synthesis, fibroblast growth, inflammation, and fibrosis at low doses [7].  
Local drug delivery systems have the capability to bypass many of the challenges of drug 
delivery, and investigations into the design of such devices are widespread, with only a few 
examples being introduced above. One avenue for the further development of these drug delivery 
systems is the use of naturally derived drug delivery systems.  
2.2.3 Benefits of Natural Drug Delivery Systems 
Effective drug treatment regimens elicit minimal immune response. An immune response 
can present as irritation and/or inflammation of the tissue, and it can be quantified by the 
population of cells containing elevated concentrations of macrophages and lymphocytes [8]. Some 
polypeptides have already been investigated and found to be accepted by the immune system. 
These include collagen, albumin, elastin, and gelatin [45]. Additionally, tolerable natural polymers 
(tested in vivo) include polysaccharides such as alginate, hyaluronic acid, dextran, and chitosan 
[45]. Naturally produced systems are desirable for drug delivery due to a variety of properties, 
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including a generally lower cost, high availability, capacity to be modified chemically, 
biocompatibility, and, in some cases, biodegradability [10]. 
The biocompatibility and somewhat complex nature of naturally-derived DDSs makes 
them of increasing interest in new drug delivery strides. For instance, natural silk has been found 
to be an effective material to construct a DDS for anti-cancer drugs [57]. Silk’s ability to alter its 
crystallinity and interact with hydrophobic, hydrophilic, or charged particles has a significant 
effect on drug retention and release [51]. In one study, a pH dependent release system for 
doxorubicin, a natural product from bacteria Streptomyces peucetius, was created using silk 
nanoparticles in which the surface of the nanoparticles were altered to have an overall negative 
charge [58, 59]. Studies on self-assembling silk hydrogels have also highlighted that the ability to 
self-assemble aided in the ability to be physically implanted [60].  
2.2.4 Plant Cell-Derived Delivery System 
Plant-derived polymers are diverse in their application: matrix systems, implants, films, 
beads, microparticles, nanoparticles, inhalable, injectable, and viscous liquids are all different 
ways in which they can be utilized [10].  
The use of total plant cell culture as a drug delivery system is appealing field of 
investigation due to many potential benefits. The culture is readily available, relatively 
inexpensive, and relatively easy to produce and maintain. It can be more environmentally friendly 
than the extraction from the naturally occurring plant. The minimization of downstream processing 
can also decrease cost by removing purification steps and decreasing production time [61]. Culture 
derived delivery systems also have potential for enhanced performance through synergistic effects 
of other plant metabolites that can increase drug efficacy [62, 63]. 
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Plants produce many different classifications of specialized metabolites (small organic 
molecule not essential for cell growth), organic compounds that potentially have different 
pharmaceutical advantages [64]. Using total plant cell culture for drug delivery would capitalize 
on the unique properties of all present metabolites. Some metabolite classes are described in Table 
1. 
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Table 1: Specialized Metabolites 
A chart of common specialized metabolites produced in plant cell culture and their 
pharmaceutical advantages. Note that various metabolites have properties that would aid 
in the effectiveness of a plant cell derived DDS. Adapted from:(Kabera, 2014 [65]). 
Metabolite 
Classification Description Pharmaceutical Usages 
Phenolics 
 
-  Synthesized by fruits, vegetables, teas, cocoa, 
and other plants that possess certain health 
benefits 
-  Anti- inflammatory 
-  Protect from oxidative stress 
-  Bactericidal 
-  Antiseptic 
-  Anthelmintic 
Flavonoids 
-  Water-soluble pigments found in the  
vacuoles of plant cells 
-  May act as (in plants): 
chemical messengers 
physiological regulators 
cell cycle inhibitors 
-  Anti-allergic, anti-cancer, anti- 
inflammatory, anti-viral 
-  Some relive fevers, eczema, asthma, 
and sinusitis 
-  Reduce the risk of atherosclerosis 
-  Reduce risk of heart disease 
Terpenoids 
-  Composed of the most important active 
compounds of plant cells – why?  
-  A tool for communication between plants and 
other organisms 
-  Disease treatment 
-  Antimicrobial and antiviral 
-  Steroids 
Essential Oils 
-  Natural aromatic and volatile compounds 
-  Provide protection to the plant from predators 
and disease 
-  Aromatherapy 
-  Antibacterial, antifungal, and antiviral 
Tannins -  Phenolic compounds that precipitate proteins -  Water soluble 
-  Astringent against diarrhea 
-  A diuretic against stomach and 
duodenal tumors 
-  Anti-inflammatory 
Glycosides 
-  Phenols, alcohols, or sulfur containing 
compounds 
-  Contain sugar and non-sugar portion 
-  Inactive until hydrolyzed by enzyme 
-  Prodrugs 
-  Anticancer agents 
-  Expectorants 
-  Sedatives 
-  Digestion aids 
Saponins 
-  Produce colloidal solutions in water 
-  Precipitate cholesterol 
-  Can lower surface tension acting as detergent 
-  Antimicrobial 
-  Hemolytic 
Alkaloids 
-  Contain basic nitrogen atoms 
-  May also contain 
 oxygen, sulfur, chlorine, bromine, and/or 
phosphorous 
-  Produced by bacteria, fungi, animals, and 
plants 
-  Narcotics 
-  Anti-cancer, anti-inflammatory, anti-
bacterial, anti-viral 
-  Treatments against malaria 
-  Immune effects 
-  Neurotoxins 
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An example of applying whole-plant metabolites as medicine is the success of whole plant 
Artemisia annua to treat malaria [66]. Recently there has been an emergence of drug resistant 
parasites which have made typical malaria treatment less effective. Artemisia annua produces the 
drug artemisinin which can interfere with heme detoxification, a requirement for parasite survival 
[66]. A recent study examined the effects of using the whole plant as an oral drug delivery system 
and found that it increases the efficacy and bioavailability of artemisinin [66]. This augmentation 
is likely because non-artemisinin metabolites with the whole plant inhibits the high metabolic 
breakdown of artemisinin by hepatic and intestinal cytochrome P enzymes which can reduce the 
bioavailability of the drug. There are also probable synergistic effects from the flavonoids in the 
whole plant which can potentiate the activity of the artemisinin [66]. Other studies have explored 
the use of bananas and other crops as a method to produce and deliver vaccines [67]. Along with 
a decrease in production costs using whole plants such as bananas, tobacco, carrots, and rice, these 
oral vaccines can increase efficacy because they mimic the natural infection, as well as increase 
both systemic and mucosal effects [67].  
Examples of these synergistic effects can be seen in various other whole plant applications. 
Liquorice is often used as an aid in detoxification as it can alter the absorption in the stomach [68]. 
For treatment of multiple sclerosis patients, processing whole cannabis plants allows for the 
retention of cannabidiol (CBD) which can increase the effects of tetrahydrocannabinol (THC), the 
psychoactive constituent, to reduce anxiety and enhance the antispastic traits [68].  It has also been 
determined that CBD has anticonvulsant effects which are also augmented by the anticonvulsant 
effects caused by THC making it an effective treatment for epilepsy [69]. Taxus cell cultures 
produces various taxanes as well as other specialized metabolites provide the potential to induce 
synergistic effects such as aforementioned natural compounds.  
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2.3. Research Plan: Taxus Cell Culture as a Drug Delivery 
System for Paclitaxel 
Overall, the desire to improve treatments and patient outcomes continues to drive 
innovation in the field of cancer treatment. How can treatments be made more effective and 
feasibly scalable, while minimizing the negative side effects often associated with cancer 
treatments? Taxus cell culture provides a promising avenue for developing alternative delivery 
methods for PTX. 
The use of total Taxus cell culture as drug delivery system offers various possibilities of 
different solid local drug delivery options, such as injectable gels, liposomes, or scaffolds. PTX is 
a hydrophobic compound that poses a problem for the use of purified PTX used in current PTX 
drug delivery. Harsh solvents need to be used for PTX to be delivered which can have severe 
negative effects on the patient. Using total cell culture, a decrease in the dangerous and cytotoxic 
side effects often associated with current delivery methods may be achieved and lower doses of 
the drug may be delivered by increasing the amount of the drug in proximity to a tumor. Local 
contact within tumor sites limits the cytotoxic effects of PTX to the affected areas decreasing side 
effect cytotoxicity throughout the body. Along with this, the cultures’ ability to produce various 
taxanes and specialized metabolites could increase the efficacy of the drug through synergistic 
effects. This study explores the potential of a total Taxus cell culture derived drug delivery system 
through the completion of the following aims:  
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Aim 1: Identify strategies to improve the concentration of cell-associated PTX in 
vitro to prepare the plant cell for use as a drug delivery system.  
Aim 2: Optimize the decellularization of plant cell culture to develop a biomaterial 
capable of delivering PTX. 
Aim 3:  Quantify the feasibility of the biomaterial through evaluation of its release 
profile in protein-saturated liquid both alone and encapsulated in a 
protective hydrogel. 
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Chapter 3: Improve Uptake and Retention of Cell-
Associated Paclitaxel 
Achieving an effective concentration of cell-associated PTX is necessary for the success 
of the targeted drug delivery system. Currently, intravenous solutions are supplied at a 
concentration of 6 mg/mL and diluted for the needs of the patient which is not feasible to achieve 
using modern cell culture methods although current research has focused on increasing PTX 
concentrations in vitro [70].  
3.1. Background 
3.1.1. Elicitation of Paclitaxel Production and Culture Treatment  
Obtaining PTX in cell culture can be difficult with naturally low production rates. The 
production of the drug is determined by a complex interaction of various steps with a multiplicity 
of rate limiting factors which makes it difficult to achieve desirable concentrations [71]. This 
project explored two methods to increase the amount of PTX in culture: elicitation with methyl 
jasmonate (MeJA) and the addition of exogenous PTX.  
Methyl Jasmonate (MeJA) Elicitation  
MeJA is a natural plant hormone which elicits the production of PTX by the Taxus 
cells. Elicitors signal environmental stresses which can stimulate the production of 
defense-related compounds and proteins including PTX, a specialized metabolite most 
likely used to protect the plant [72]. A study found that the introduction of 100 µM 
MeJA in culture can increase the production of PTX by more than 50% yielding a 
concentration of 1.1 mg/L two days after elicitation [72]. Another study found that 
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cells elicited on day 8 of suspension culture with the same 100 µM  MeJA addition 
can achieve concentrations as high as 14.4 mg/L 10 days after elicitation [73]. 
Response to the hormone varies greatly between cell line, affecting the increase in 
PTX production observed, due to this an investigation into the response of the cell 
lines needed for this project is necessary [73].  
Treating Cultures with Exogenous Paclitaxel 
Exogenously adding purified PTX to cultures is an effective and calculated method to 
control the total amount of PTX in a culture and to observe how different concentrations 
of PTX can affect cell growth and behavior [71].  
Both methods increase the concentration of PTX in culture, but there are additional, potentially 
more effective methods that could be used. Other alternative methods have been explored for 
increased PTX production including the addition of silver-based compounds and/or other plant 
hormones [74]. 
A wide variety of methods and agents have been studied to increase cellular production of 
PTX. Some abiotic elicitors include metal ions and inorganic compounds such as silver complexes, 
copper sulphate, and cobalt complexes [74, 75]. Many silver containing compounds function as 
anti-ethylene agents, thought to increase PTX production [74]. Biotic elements functionable as 
elicitors include fungi, bacteria, viruses, cell wall components, and various chemicals such as 
jasmonates (anti-ethylene agents), arachidonic acid, and salicyclic acid, synthesized by the plant 
at sites of attack from pathogens or herbivores [75]. Recently, cyclodextrin and coronatine have 
been noted as successful elicitation agents [76]. Coronatine, a bacterium produced toxin can reduce 
growth capacity of cells and elicit PTX production in Taxus [76]. Cyclodextrin can counteract the 
reduced growth induced by coronatine and induce a cellular defense response through PTX 
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production [76]. Additionally, cyclodextrin can complex with poorly soluble compounds to 
facilitate in cellular excretion [76]. Combining cyclodextrin with MeJA has shown to increase 
PTX elicitation than either compound used alone [76]. Metabolic engineering of the Taxus genome 
could be employed to fine tune the biosynthetic pathway to promote PTX production, but this 
approach is difficult partially due to the slow growth of Taxus and the difficulty of genome editing 
[75]. 
For this project, along with an increase in PTX production and increase in the concentration 
of cell-associated PTX, is also necessary to retain sufficient PTX for accurate quantification 
throughout decellularization, as well as for the development of a feasible DDS. The processed 
biomass should contain enough PTX to be effective in tumor treatment. A beneficial approach to 
further facilitate PTX cell association would be to block PTX transport from the cell and 
accumulate the drug intracellularly. 
PTX is a specialized metabolite within the terpeoid classification so while the exact 
transport mechanisms of PTX within the cells are unknown, studies on the transport of related 
metabolites in other plant species offer insight into the potential transport mechanism of PTX. It 
is suspected that PTX transport is facilitated in part by ATP-binding cassette (ABC) transport 
proteins, but continued research into specialized metabolite transport suggests that there could be 
multiple PTX transport mechanisms [77, 78]. ATPase inhibitors are also useful because they block 
the ATP proton pumps which provide the energy necessary for transport [64]. These concepts are 
important to take into consideration as they could affect Taxus cell culture and PTX transport when 
attempting to obtain improved cell-associated accumulation. 
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3.1.2. Preliminary Inhibition Research 
Prior studies conducted within the Roberts’ lab have investigated the effects of inhibitors 
on the transport of PTX in the Taxus cell culture. One study conducted during a 2017-2018 MQP 
looked at the effects of various transports inhibitors which covered two groups: ABC transport 
inhibitors and an ATPase inhibitor [79]. This study was conducted over the course of 24 hours 
with the short-term effects of verapamil increasing the concentration of cell-associated PTX 
(Figure 3).  
 
Figure 3: The effect of inhibitor concentration (50µM and 100µM) on PTX concentration 
in P093X Taxus culture over time. Inhibitors tested were verapamil, genistein, cyclosporine 
A, and vanadate. Cell associated and extracellular (media) PTX was tested (mg/L) after 
inhibitor addition at 1.5, 3, 6, and 24 hours *=p<0.0332, **=p<0.0021, ***=p<0.0002 and 
****=p<0.0001 [79].  
Following this study, a summer research project by Dasia Aldarondo studied the effects 
that extended exposure to verapamil could have on a culture’s PTX transport. This study was 
conducted on both elicited cells and unelicited cells (treated with a 20 mg/L concentration of PTX). 
Various concentrations of verapamil were investigated in staggered additions. Results from this 
study concluded that verapamil could not only increase the amount of cell associated PTX in the 
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cell but could also increase the total PTX in the media of culture as well. This is represented in 
Figures 4 and 5. 
      
Figure 4: Concentration of accumulated 
PTX measured over 27 days in elicited 
21260C culture with various amounts of 
verapamil (0µM, 50µM, and 100µM).  
 Figure 5: Concentration of accumulated 
PTX measured over 21 days of elicited 
21260C suspension cultures treated with 50 
µM verapamil. Flask 1 and Flask 2 
represent two biologically different flask 
under the same treatment.  
These data align with another study recently published that looked at the effects of different 
inhibitors on the production of isoflavones in Trifolium pratense L. cells [80]. This study 
concluded that verapamil (ABC protein inhibitor) increased the concentration of genistin both 
inside and outside of the cells [80]. 
3.1.3. Taxus Culture Characteristics 
Overall culture health, viability, and general characteristics are factors to explore in 
bioprocess development. Healthy cultures are essential to ensure that bioproduction of a delivery 
system is feasible. One method to assess cell viability is through propidium iodide (PI) staining. 
PI binds to the DNA of dead cells but is incapable permeating the cell wall of living cells and thus 
is a beneficial qualitative tool to measure cell death. An effective approach to study the viability 
of cell culture is to tract cell growth and culture biomass [81]. Taxus cell culture grows in 
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aggregates and so analysis of individual cell size is very difficult and correlations of volume to dry 
weight can be used to measure cell mass [81].  
In the scope of this project cell viability is important for increased PTX production but 
following PTX accumulation cells must be dried for further processing. A common method 
utilized to dry cells is lyophilization, or freeze drying under a vacuum [82]. While lyophilization 
kills the cells, it allows for the retention of nonvolatile specialized metabolites such as PTX [82].  
 
3.2. Methods 
To increase the amount of cell-associated PTX concentrated in the final lyophilized product to 
serve as a DDS, two approaches were explored. 
1. Manipulating cellular PTX transport mechanisms 
2. Exploiting PTX’s hydrophobic properties 
Experimental procedures for each approach are outlined in this chapter. 
3.2.1 Plant Cell Culture Maintenance 
21260C (Taxus chinensis) and 48-82-A (Taxus cuspidata) cells were grown and maintained 
in 50 mL liquid suspension cultures and transferred every 14 days. Media consisted of 20 g/L 
sucrose (Caisson Laboratories, Smithfield UT), 3.21 g/L Gamborg-B5 (PhytoTechnology 
Laboratories, Lenexa KS), 120 µL/L benzyl adenine (Sigma-Aldrich, St. Louis MO), 2.7 mL/L 1-
napthalenacetic acid (Sigma-Aldrich, St. Louis MO).  The final solution was brought to pH 5.5 
using 1 M sodium hydroxide before being aliquoted and autoclaved in 125 mL Erlenmeyer flasks 
containing 40 mL of media at 121 °C for 30 minutes. Taxus cell cultures are transferred every 14 
days to new media; day seven in culture is when the Taxus reaches stationary, non-growth phase, 
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which is when most PTX is produced [83]. To transfer cultures, 10 mL of day 14 cell culture was 
transferred in a sterile environment using serological pipettes to fresh media supplemented with 
2.5 mL of filter-sterilized antioxidant solution containing 2.5 mg/mL ascorbic acid (Fisher 
Scientific, Hampton NH), 2.5 mg/mL citric acid (PhytoTechnology Laboratories, Lenexa KS), and 
14.6 mg/mL L-glutamine (Caisson Laboratories, Smithfield UT). Cultures were incubated at 23 
°C in the dark and shaken at 125 RPM.  
3.2.2 Manipulating Transport Mechanisms 
Inhibitor Study 
To examine the effects of three ABC transport inhibitors and one ATPase inhibitor on PTX 
concentration in cultures over 21 days, cultures were elicited with methyl jasmonate (MeJA) 
(Sigma-Aldrich, St Louis MO, 392707) and treated with inhibitors as described in Table 2. Two 
ABC transporter inhibitors: cyclosporine A (Cayman Chemical, Ann Arbor MI, 12088) and 
verapamil (Acros Organics, Geel (Belgium), 329330010) were investigated alongside the ATPase 
inhibitor vanadate (MP Biomedicals, Solon OH, 218058). Inhibitors were selected from 
preliminary data from a previous MQP that examined the effects of inhibitors over a 24-hour time 
span (Section 3.1.2).   
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Table 2: Inhibitor Test Groups 
The experimental test group names and the treatment conditions  
Test Groups (Inhibitor) Conditions 
Control 
 
No treatment 
Elicited 
 
200 µM MeJA  
Elicited +Verapamil 200 µM MeJA  
50 µM Verapamil (ABC Transport Inhibitor) 
 
Elicited + Cyclosporine A 200 µM MeJA  
50 µM Cyclosporine A (ABC Transport Inhibitor) 
 
Elicited + Vanadate 200 µM MeJA  
50 µM Vanadate (ATPase Transport Inhibitor) 
 
Elicited + Verapamil and 
Vanadate 
200 µM MeJA  
50 µM Verapamil (ABC Transport Inhibitor) 
50 µM Vanadate (ATPase Transport Inhibitor) 
 
All test groups, apart from the control group, were treated with MeJA and their respective 
inhibitors on day seven of culture. On this day, the culture was divided into 50 mL flasks 
containing 25 mL of culture (conditioned media and cells). MeJA was utilized to increase the 
natural production of PTX as well as other specialized compounds to be investigated for the 
delivery system. Verapamil and vanadate were combined to determine if inhibiting both types of 
transport mechanisms could result in a significant increase of cell-associated PTX. 
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Two 1 mL samples of the total cultures and two 1 mL samples of media of each condition 
were taken 7 and 14 days after treatment with inhibitors. Samples were weighed and stored at -
20°C for later UPLC processing and quantification (Section 3.2.4). Culture aggregate size 
distribution of total culture samples (2 mL, one sample per treatment flask) were analyzed with 
the Coulter Counter (Section 2.2.5) to determine effects of inhibitors on culture growth and 
aggregation on days 7 and 14 after treatment. Finally, cell viability was qualitatively assessed 
microscopically with total culture samples from each treatment stained with 2.5 µL of propidium 
iodide on days 7 and 14 after treatment.  
 
Figure 6: Flow chart of the sampling procedure for testing inhibitor effects. 
3.2.3 Exploiting Paclitaxel’s Insolubility 
Two experiments were performed to determine the effect of lyophilization and washing on 
Taxus cultures and PTX retention throughout the process. The preliminary experiment was to 
compare changes in weight during the lyophilization and washing of total culture versus the 
lyophilization and washing of only cells. The second experiment aimed to determine if and where 
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PTX was retained throughout the lyophilization process as well as changes in weight throughout 
the process.   
Lyophilization Study: Changes in Weight 
This experiment was conducted to ensure that there was no significant final mass difference 
between lyophilization of a complete culture sample (media and cells) and a cell sample (cells 
only) post washing. To execute this experiment, two 50 mL conical tubes were filled with equal 
volumes of well mixed culture and weighed. From one tube, the media was removed, and the 
remaining contents of the tube were washed with deionized (DI) water three times and reweighed. 
The other sample tube was left untreated. Both tubes were flash frozen using liquid nitrogen then 
lyophilized overnight on a shelf lyophilizer (VirTis BenchTop Pro with Omnitonics, SP Scientific, 
Stone Ridge, NY) and weighed. Finally, both samples tubes were washed again with DI water, 
dried using Buchner funnel vacuum filtration, and weighed. 
Lyophilization Study: PTX Association 
To determine if PTX would remain associated with samples throughout the lyophilization 
and washing process, the following experiment was performed. Samples were analyzed for PTX 
with UPLC at three points in the process: before lyophilization, after lyophilization, and after 
lyophilization and washing.  
A total of five treatments were tested using 48-82A-32 (Taxus cuspidata). Three of the 
treatments included samples from elicited cells (elicited with MeJA on day 7 of culture then 
sampled 14 days later): total culture, cells only, and media only. Two of the treatments were from 
unelicited total culture samples loaded with 20 mg/L PTX (Alfa Aesar, Ward Hill, MA) at different 
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time points: two hours before flash freezing, and immediately before flash freezing. An outline of 
these treatments can be seen in Table 3.  
Table 3: Lyophilization Treatments 
 The experimental test group names and the treatment conditions.  
Treatment Condition 
PTX 0 20 mg/L PTX (added directly before lyophilization) 
PTX 2 20 mg/L PTX (added 2 hours before lyophilization) 
Elicited Total Culture 200 µM MeJA 
Elicited Cells Only 200 µM MeJA (Media Removed) 
Elicited Media Only 200 µM MeJA (No Cells Sampled) 
 
Nine 1 mL samples were taken for each treatment into pre-weighed 1.5 mL microcentrifuge 
tubes, outlined in Figure 7. Total culture samples were taken using a 1 mL cut pipette tip, the 
culture flask was stirred as the sample was taken.  For cell only samples, a 1 mL well mixed total 
culture sample was taken and weighed. They were centrifuged at 15,000 rpm for 5 minutes, and 
media was removed with a 200 µL pipette tip and the samples were weighed again. Media only 
samples were taken with a 1 mL pipette tip from culture flasks that had been allowed to settle so 
that only media was removed. All samples were then flash frozen with liquid nitrogen before being 
stored in a –20 °C freezer until lyophilization or processing. 
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Figure 7: Flow chart of the sampling procedure for lyophilization experiment. 
 
Samples were freeze dried with a shelf lyophilizer for 16 hours. After lyophilization, all 
samples were weighed and stored at -80 °C. Samples that were not lyophilized were stored at -20 
°C.  
Relevant samples were washed (post-lyophilization) before UPLC processing. To do this, 
1 mL of deionized water was added and vortexed briefly. The samples were then centrifuged 
(Eppendorf, Hamburg Germany, Model 5418R) for 4 minutes at 15,000 RPM. The remaining 
liquid was removed with a 200 µL pipette tip. This washing process was repeated three times. 
After, the samples were re-weighed and stored at -80 °C. All samples were analyzed for PTX 
quantification following the procedure in Section 3.2.4. 
3.2.4 UPLC Preparation Procedure 
To prepare samples for UPLC processing, they underwent an organic extraction to remove 
PTX from the culture matter. Samples were first placed in an evaporative centrifuge (Vacufuge 
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plus, Eppendorf, Hamburg Germany) overnight (approximately eight hours) under aqueous 
evaporation conditions (1400 rpm, suction capacity: 1.8 m3/h). After samples were completely 
dried, they were resuspended in 1 mL acidified methanol (0.01% acetic acid in methanol) briefly 
vortexed, then sonicated (Aquasonic 75HT, VWR, Radnor PA) for 30 minutes on ice. After 
sonication, large particulates that remained in the samples were manually broken using a spatula 
combined with vortexing. Samples were sonicated on ice again (20 minutes), incubated on a shaker 
(20 minutes), and centrifuged at 15,000 RPM (20 minutes). The supernatant (800 µL) was removed 
with a 1 mL pipette and transferred into a new microcentrifuge tube. These samples were returned 
to the evaporative centrifuge for approximately 2 hours until samples were dry using alcohol 
evaporating conditions (1400 rpm, suction capacity: 1.8 m3/h). Finally, samples were stored in a –
20 °C freezer until preparation for UPLC quantification. 
UPLC samples were dissolved in 25 µL methanol, 35 µL acetonitrile, and 40 µL nano-pure 
water. Between each addition of solvent, the samples were briefly vortexed and sonicated. When 
the sample was fully dissolved, it was filtered through a 0.22 µm polyvinylidene difluoride filter 
using a 1 mL syringe into a low volume UPLC vial. A cap was crimped onto the top of the vial 
and any air trapped in the sample was removed. Samples were then analyzed by UPLC (Waters, 
Milford MA, Acquity UPLC H-Class), which consisted of one 10 µL injection and a 6-minute 
separation time in which molecules are separated in a 70:30 (v:v) water-acetonitrile solvent in a C 
18 2.1x50mm, 1.7µm column. The chromatograms were analyzed at a wavelength of 228 nm and 
compared to a standard curves produced by 0, 12.5, 25, 50, and 100 mg/L standards containing 
PTX, baccatin III, and 10-deacetylbaccatin III (Alfa Aesar, Ward Hill, MA) in 70:30 (v:v) water: 
acetonitrile.  
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3.2.5 Coulter Counter Methods 
The size distribution of aggregates present in culture were measured with a Multisizer 3TM 
Coulter Counter (Beckman, Brea CA). The analysis procedure for the Coulter Counter was adapted 
from that of Kolewe et. al. [81]. From each sample, 2 mL of total cell and media sample was taken 
with a 5 mL cut pipette tip and put into a round bottom 500 mL Coulter Counter flask. The flask 
was then brought to volume with the diluent, a 65:35 water to glycerol solution (v:v) (Thermo 
Fischer Scientific, Waltham MA, A16205-0D) with 6.34 g/L sodium chloride (Sigma-Aldrich, St 
Louis MO, S5886) and 0.32 g/L sodium azide (Acros, New Jersey, 19038-1000). The diluent and 
sample were stirred and analyzed for size distribution by the Coulter Counter. The size distribution 
data collected from each sample was further processed in Microsoft Excel to approximate dry 
weight of each sample using a correlation between total volume and volume percent developed by 
Kolewe [81]. 
 
3.3 Results and Discussion 
3.3.1 Manipulating Transport Mechanisms 
Inhibitor study: 
Results from the inhibitor study were inconclusive with only 23% of 144 samples 
containing identifiable levels of PTX. Samples that did show PTX were in low yields in 
comparison to past results. Imaging and Coulter Counter data (Figures 9-11) showed that most of 
treated flasks were no longer viable within the first 7 days of the treatment (day 14 of culture). 
Visual observations suggested viability decrease even earlier at day 2 for some of the treated cells 
indicated by dark green/brown culture as shown in Figure 8.  
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Figure 8: Examples of unviable cultures observed after vanadate treatment. 
 
Microscope images of propidium iodine stained samples on days 14 and 21 of cell culture (days 7 
and 14 of treatment) gave qualitative evidence of cell death within cultures, as shown in Figure 9. 
This cell death could be attributed to various reasons including contamination or devastating stress 
induced by elicitation.  
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Figure 9: Shows a qualitative analysis of the viability of cultures for each treatment at days 
14 and 21 of cell culture (days 7 and 14 after treatment). The red staining indicates a dead 
nucleus, increased red depicts a culture with poor cell viability. Many flasks show a 
considerable amount of PI fluorescence by day 14 of culture (day 7 of treatment) an 
indication of culture death with the exception of the control cells which showed the 
anticipated low concentration of dead nuclei. 
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Coulter Counter analysis was used to further understand these observations at the same 
time samples for UPLC and microscope images were taken. The Coulter Counter data were used 
to approximate correlated dry weight of the cells through particle diameter. Figure 10 shows the 
average particle diameter of each treatment at both days.  
 
Figure 10: Shows the mean particle diameter of each treatment at days 14 and 21 after 
treatment, where V+V represents vanadate and verapamil. The error bars represent the 
standard deviation of each of the three flasks from each other, where one trial per flask was 
performed.  
In all cases, the mean particle diameter increases over time. It was observed that the treated 
cells have larger diameters compared to control cells. This could be an indication of cell death 
caused by stresses that cause cell plasma membrane rupture and is preceded by the swelling of 
various organelles, increasing particle diameter [84]. This hypothesis would support the 
quantitative observations made from the PI stained microscopy pictures. 
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Figure 11: Shows the correlated dry weight calculated from the mean particle diameter 
data using a relationship developed by Kolewe et al. [81], shown above in Figure 10. The 
error bars represent standard deviation of the three samples tested for at each data point. 
As before, V+V represents the vanadate and verapamil treatment.   
Like the mean particle diameter, correlated dry weight increased with time. Deviations in 
trends may be due to the dry weight calculation accounting for the number of particles in each 
sample. Both treating the cells and time scale of culture can affect the average dry weight. 
3.3.2 Exploiting Paclitaxel’s Insolubility 
Initial results were utilized to determine if the lyophilization of total culture (both cells and 
media, well mixed) followed by washing significantly affected the resulting mass. Data show that 
there was no significant difference in final weights between samples washed after lyophilization 
or those washed prior to lyophilization as shown in Figure 12. With this knowledge all further 
experiments used cells lyophilized in media (total culture). Also using these data, a correlation 
between the mass of the total lyophilized culture and cells only was determined so the 2 mg 
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samples of cells necessary for all the following experiments could be achieved. It was determined 
that four times (8 mg) the mass of total culture sample is necessary to yield the desired amount of 
cell biomass (2 mg). This correlation was used for following experiments that used cell lyophilized 
in media. 
 
Figure 12: Shows mass fraction on a gram per gram basis of two 20 mL total culture 
samples normalized to initial total culture mass. The lyophilized mass fractions represent 
differences between the mass of washed cells (media removed) and total culture sample 
after lyophilization. The washed mass fractions represent mass fractions after 
lyophilization and washing, leaving only wet biomass.  
Lyophilization Study:  
The goal of the lyophilization study was to determine if lyophilizing total culture could 
increase the amount of cell associated PTX within a sample. To determine the impact that both 
cells and media had on the concentrations of PTX, elicited culture samples of only cells, only 
media, and both cells and media were compared prior to lyophilization, after lyophilization, and 
after washing with deionized (DI) water. Results were used to verify a mass balance on PTX 
through the various steps in the process and to determine if any PTX was lost during any point of 
process. Along with the comparison of the concentration for sample type there is also a comparison 
to the theoretical total to fulfill the mass balance. Results were not consistent with this expected 
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mass balance. The results also demonstrated no significant variation in total PTX between each 
step of the lyophilization process, as shown in Figure 12.  A significant decrease in total PTX after 
washing the cells post-lyophilization was observed. This loss is undesirable for product 
development both from a monetary and feasibility perspective. The elimination of any unnecessary 
post-lyophilization wash steps or using alternative methods of washing could maximize PTX 
retention. 
 
 
Figure 13: Concentration of PTX in a 1 mL sample. These data shows the comparison of 
PTX at each stage of the cell lyophilization process for an elicited culture both in total and 
split into cell and media components. The error bars represent standard deviation amongst 
three biological replicates.  
The total PTX amount for samples of cultures that had additions of PTX 2 hours and 0 
hours before lyophilization was also compared. This set of samples demonstrated a significant 
decrease in the amount of PTX post-washing. This could be due to a lower degree of cell-
association of the PTX when added extracellularly or the binding of PTX to extracellular materials 
that result in PTX removal during the wash steps.  The two time points chosen did not show a 
significant difference in concentration of PTX, so it is unclear if time influences the association of 
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PTX with the sample (Figure 14). An in-depth absorption study is required to better understand 
the kinetics.  
 
Figure 14: Concentration of PTX/biomass of cells (mg/µg) in a 1 mL sample. These data 
show the comparison of PTX at each stage of the cell lyophilization process for a culture 
with the addition of PTX (20 mg/L) 2 hours (t = 2) and at the time of lyophilization (t = 0) 
in comparison to an elicited culture (No PTX). Error bars represent standard deviations 
amongst three biological replicates. *=p<0.03, **=p<0.007 in comparison to the 
lyophilized and washed No PTX samples. 
 
3.3.3 Conclusions 
These studies suggest that the best method to yield significant amounts of PTX in culture 
to develop an effective delivery system is using MeJA elicited culture that is subsequently treated 
with 20 mg/L PTX (or even potentially higher concentrations) in culture prior to lyophilization. It 
is understood that this method does not optimize the process, as the best process would utilize only 
the PTX produced by the plant cell suspension cultures and maintain its concentration after 
washing. There are currently ongoing efforts to increase PTX production and accumulation, some 
of which are discussed further in Section 6.1.1. With this conclusion in mind all subsequent 
experiments were executed using cells that were both MeJA elicited and treated with 20 mg/L 
PTX. 
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Chapter 4: Preparation of a Drug Delivery System 
 
4.1. Background 
In applications where foreign biological material is introduced to mammalian tissue, it is 
important that foreign DNA is not brought in to the system as to avoid an immune response [85]. 
In delivery systems stemming from living organisms or cells, decellularization (the removal of 
DNA) is necessary in order to prevent this issue [85]. This is the case for a Taxus cell derived drug 
delivery system, requiring the decellularization of the cell aggregates to remove DNA which may 
be harmful to healthy human tissue [85]. This must be executed while also ensuring that a large 
enough concentration of PTX is maintained to ensure effective treatment.  
4.1.1. Taxus Cell Culture Processing 
The use of PTX as a therapy presents some unique challenges, mainly due to its low 
solubility in aqueous solutions [41]. It is believed that PTX retention in processed culture will aid 
in bypassing this challenge by permitting direct delivery, but it raises concern about the mechanism 
in which the PTX will be released from the system upon placement on or in the tumor tissue 
(explored in Chapter 5). Biocompatibility of the drug delivery system with mammalian tissue is 
an important consideration to avoid an immune response. 
Specialized metabolites produced by plants are of interest in the medical field because of 
their bioactive properties; PTX being an example of this. In some cases, synergistic effects 
between metabolites can help overcome cases of drug resistance and improve treatment [65]. 
Additional effects of specialized metabolites that could potentially be found in plant cell culture 
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as previously discussed. Lyophilization of plant material generally preserves the chemicals within 
it, especially those that are non-volatile, protecting the medicinal value [82].  
4.1.2. DNA and Drug Delivery 
Decellularization minimizes the effect of foreign DNA on mammalian tissue. DNA has a 
strong negative charge and is susceptible to nucleases in mammalian tissue [86]. Foreign DNA can 
elicit a cascade of responses by the immune system including the proliferation of B cells, white 
blood cells, and dendric cells [87]. In humans, nonparenchymal liver cells work to clear foreign 
DNA from circulation in the bloodstream [86]. Taxus suspension culture cell lines contain varying 
amounts of DNA that can change over time due to chromosomal rearrangements [88]. Based on 
studies that used flow cytometry, nuclear DNA content of Taxus cells varies between 21.06 and 
62.30 pg/cell [88, 89]. DNA can be enzymatically degraded with deoxyribonuclease I. DNase 
cleaves DNA randomly in the presence of Mg2+ ions and uniformly in the presence of Mn2+ ions 
[90].  
4.1.3. DNA Quantification 
DNA quantification of cells through PicoGreen Assay requires lysing of the cell wall. This 
can be done with cell-wall degrading enzymes such as cellulase, hemicellulase, and macerozyme. 
Cellulase (derived from Trichoderma verde) functions through breaking down cellulose present in 
the cell wall by hydrolization of its 1,4-glucosidic linkages [91]. Hemicellulase (derived from 
Aspergillus niger) is a combination of glycolytic enzymes that break down sugars present in 
hemicellulose making up the cell wall [92]. Hemicellulase usually contains xylanases that degrades 
xylan, a component of hemicellulose and mannanases, enzymes that degrade mannans, also present 
in hemicellulose [93, 94]. Macerozyme (derived from Rhizopus sp.) is a blend of pectinases that 
cleave pectins in the cell wall by hydrolysis [95]. It is important to note that PTX may be affiliated 
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with the cell wall, as the use of cell-wall degrading enzymes has been seen to release PTX in 
surrounding cell media [96]. Therefore, degradation of the cell wall is mainly important to DNA 
quantification, not the decellurazation process itself in the context of this project. 
 
4.2 Methods 
This study aimed to investigate the capacity for cultures to retain PTX and other specialized 
metabolites through decellularization, the elimination of DNA. The following procedure describes 
the decellularization process and the steps taken to analyze content of DNA, PTX, flavonoids, and 
phenolics throughout processing of Taxus cultures. 
4.2.1 Quantifying DNA Removal 
The first goal was to quantify total DNA in untreated samples. Lyophilized (2 mg, washed 
before lyophilization) culture samples were treated with three enzymes and one control, as 
described in Table 4.  
Table 4: DNA Removal Test Groups 
 Enzymatic test group names and amounts of treatment added. The primary addition was 
added to triplicates of 2 mg lyophilized cells (washed preceding lyophilization) and 
incubated for one hour at room temperature before the secondary addition was added. 
Treatment (in triplicates) Primary Addition (200 µL) Secondary Addition 
Hemicelluase 5% Hemicelluase in PBS 
200 µL Nuclear Lysis Buffer 
0.10 g Bullet Blender Beads 
Celluase 5% Celluase in PBS 
Macerozyme 5% Macerozyme in PBS 
Buffer Only (Control) PBS 
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Each of the four treatments tested 2 mg of washed then lyophilized cell samples in 
triplicate. The three enzymes tested: hemicellulase (Sigma-Aldrich, St Louis MO, H-2125), 
cellulase (bioWORLD, New York NY 21500003-1), and macerozyme (ICN Biomedicals Inc, 
Aurora OH, 152340) were mixed in 0.1 M phosphate buffered saline (1x PBS) (Fisher Scientific, 
Hampton NH, BP2944-100) for a 5% (w:v) solution. Nuclear lysis buffer was made from a solution 
of Tris EDTA (TE) buffer containing 0.1% Triton X-100 detergent (Sigma-Aldrich, St Louis MO, 
9002-93-1). A flow chart of the experimental process can be seen in Figure 15.  
A primary addition of 200 µL of each enzyme solution (or PBS in the Buffer Only 
treatment) was added to each lyophilized cell sample in triplicates and incubated for one hour. 
Following incubation, each sample was diluted with 200 µL nuclear lysis buffer and approximately 
0.10 g of 0.5 mm diameter zirconium silicate beads (Next Advance, Troy NY). Samples were 
ground in a Bullet Blender (Next Advance, Troy NY) for 8 minutes. After grinding, samples were 
centrifuged at 15,000 RPM for 8 minutes, and 20 µL of the supernatant was analyzed via the 
PicoGreen Assay (Section 4.2.3). The treatment that provided the greatest DNA release was used 
preceding the following PicoGreen Assays.  
 
Figure 15: Flow chart of the steps for the experiment to determine which method is the 
best for DNA extraction. 
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4.2.2. DNAse Treatment to Degrade DNA  
This study investigated two test groups of 21260C (Taxus chinensis), untreated (control) 
and MeJA elicited + 20 mg/L PTX (treated). On day 21 of culture, 1 mL mechanically 
homogenized (BioSpec Products, Inc., Bartlesville OK, Tissue TearorTM) culture samples were 
taken in triplicate from both test groups and stored at stored at -20 °C until processing. All the 
remaining cell culture was then lyophilized and stored at -80 °C until further processing.  
Eight milligrams of treated and lyophilized total culture samples were weighed into 1.5 mL 
microcentrifuge tubes. Samples were treated with DNase, and triplicates were used for both DNA 
and PTX quantification. DNA quantified samples followed the DNA extraction procedure outlined 
in Section 4.2.1 followed by the PicoGreen Assay (procedure in Section 4.2.3) and PTX quantified 
samples were processed with UPLC. One DNase+ treated sample was reserved for imaging. All 
treatments were compared to triplicates of samples incubated in a buffer absent of DNase and 
triplicates of samples which underwent no treatment at all. These procedures are presented in 
Figure 16. 
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Figure 16: Flow chart of the steps for the DNase experiment split into elicited and 
unelicited cells. 
 
Additionally, 6 (8 mg) total lyophilized culture samples of both Treated and Control cells were 
designated for the phenolics and flavonoids assays described in Section 3.2.4.  
The decellularization procedure was designed to remove DNA from the lyophilized cells 
followed by DNA quantification steps to ensure that the DNA was degraded. A DNase buffer 
consisted of DNase enzyme, (Sigma-Aldrich, St. Louis MO, D5025) and Dulbecco’s PBS (DPBS), 
PBS with Ca2+ and Mg2+ (Thermo Fisher Scientific, Waltham MA, 14080-055) to create a 1 mg 
DNase/mL solution. DNase buffer (500 µL) was added to each 8 mg sample and degassed under 
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house vacuum with a desiccator until gas trapped in samples was removed. Samples that were not 
treated with DNase were treated with 500 µL of DPBS. +DNase and –DNase samples were all 
incubated for 30 minutes at 37 °C. The samples were centrifuged (15,000 RPM for two minutes) 
and the initial supernatant was removed and saved for UPLC quantification. Samples were washed 
four times with PBS (volumes of 500 µL, 700 µL, 900 µL, 900 µL), centrifuged (15,000 RPM for 
two minutes) between each wash. 
4.2.3 PicoGreen Assay Procedure 
DNA concentration of samples were quantified using fluorometric assay with the Quant-
iTTM PicoGreenTM dsDNA Assay Kit (Thermo Fisher Scientific, Waltham MA, P11496). Samples 
were prepared through the DNA release protocol outlined in Section 4.2.1. A stock solution of 
98.2 µg/mL purified genomic plant DNA was diluted in 0.01% Triton X-100 TE buffer for DNA 
standards of the concentrations: 0, 0.0049, 0.015, 0.044, 0.131, 0.394, 1.183, and 3.556 µg/mL. 
The working assay solution was prepared by adding 16 µL of PicoGreen Assay reagent to 3.72 
mL of 1X TE Buffer. In a black 96 well plate, 50 µL of the working assay solution and 50 µL of 
each sample supernatant or standard was added to individual wells. The plate was incubated at 
room temperature for 5 minutes, then the florescence was read with a F535 emission filter on a 
Victor3 1420 Multilabel Plate Reader (PerkinElmer, Waltham, MA). 
4.2.4 Flavonoid and Phenolic Assay Procedures 
Sample Preparation   
For both the phenolics and flavonoids assays the following sample preparation steps were 
taken. For samples taken from suspension, 1 mL well mixed samples were taken and stored at -80 
°C. For lyophilized cultures, 8 mg of cell sample was weighed out into a microcentrifuge tube, and 
half were washed with DI water. The day before the assay was run, all samples were dried 
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overnight via evaporative centrifuge on the aqueous evaporation setting (V-AQ). Both the dried 
suspension cultures and the lyophilized samples were resuspended in 500 µL of acidified methanol 
(0.01% acetic acid). The samples were then vortexed and broken up mechanically with a spatula, 
similarly to the protocol for UPLC preparation. The samples were then centrifuged at 
15,000 RPM for 10 minutes.   
  
Phenolics Assay    
The following components were combined in a microcentrifuge tube; 4 µL of the 
sample supernatant,16 µL of acidified methanol, 40 µL 0.2M Folin-Ciocalteau reagent, and 160 
µL 700 mM sodium carbonate (Fischer Scientific, Hampton NH, S263-500). The assay was 
incubated for 10 minutes at room temperature, and then centrifuged at 15,000 RPM for one minute. 
For each sample, 200 µL of the supernatant was transferred to a 96 well plate and the colorimetric 
absorbance was read at 750 nm on a colorimetric plate reader (Accuskan Go, Fisher Scientific, 
Hampton NH). These readings were quantified to phenolic concentration using gallic acid as a 
standard at 0.0 mg/mL, 0.025 mg/mL, 0.05 mg/mL, 0.075 mg/mL, 0.10 mg/mL, and 0.20 mg/mL.   
 
Flavonoids Assay   
The following reagents were placed directly into 96 well plates: 25 µL of the 
sample supernatant, 50 µL water, and 75 µL sodium nitrite (Acros, New Jersey, 42435-5000) (6 
g/L). These were incubated for 30 seconds. Next, 75 µL aluminum chloride (Sigma-Aldrich, St 
Louis MO, 7784-13-6) (22 g/L AlCl3·6H2O) was added, followed by another two minutes 
incubation. Finally, 75 µL 0.8 M sodium hydroxide (Sigma-Aldrich, St Louis MO, 1310-73-2) 
was added to each well and the colorimetric absorbance was read at 490 nm. These readings were 
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compared to standards of catechin (Cayman Chemical, Ann Arbor MI, 70940) at 0.0 mg/mL, 0.1 
mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.6 mg/mL, 0.8 mg/mL, and 1.0 mg/mL.  
4.2.5 Nuclear DNA Imaging Procedure  
Three 8 mg samples of lyophilized 21260C (Taxus chinensis) culture that had been elicited 
with MeJA (200 µM seven days preceding lyophilization) and loaded with PTX (20 mg/L) 
preceding lyophilization were taken for nuclear DNA imaging with Hoechst Stain (Hoechst 33342, 
Tocris Bioscience, Bristol United Kingdom, 5517) to visualize the effect of DNase treatment on 
DNA concentration. Treatments examined were lyophilized only (as a control), DNase+, and 
DNase-. DNase+/- treatments were performed as described in Section 4.2.2. After appropriate 
processing steps, each sample was formalin fixed by adding 0.5 mL of 4% paraformaldehyde 
(PFA) (Acros, New Jersey, 30525-89-4) in PBS to each sample and incubating for 2 hours. 
Samples were centrifuged briefly, and the PFA supernatant was replaced with 0.5 mL PBS and 
stored at 4° C until imaging. 
For staining, 0.5 µL of 2 µg/mL Hoechst stain in PBS was added to each sample and 
incubated for 30 minutes in the dark at room temperature. Preliminary images did not appear to 
show as many nuclei as expected, so 0.1 µL of Hoechst stain (2 µg/mL) was added to each sample 
and incubated for approximately three additional minutes. Images were taken at 20x magnification 
at brightfield (exposure time of 500 milliseconds) and fluorescence (exposure time of 250 
milliseconds) on a Nikon Eclipse E600 microscope (MVI, Avon MA). The exposure time was 
modified as necessary for image clarity. 
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4.3 Results 
4.3.1 Determining DNA Release Protocol 
 
Figure 17: Concentration of DNA (µg/mL) in solution after non-elicited lyophilized plant 
cells were treated for DNA extraction. Error bars represent standard deviations of three 
biological samples which we each averaged from three technical replicates. The buffer only 
control lacks error bars because two of the biological replicates were lost during sampling.  
Figure 17 represents the data collected to determine the best method to quantify the amount 
of DNA removed in future experiments. These data suggest that both cellulase and hemicellulase 
efficiently degraded the cell wall to release DNA. Cellulase was utilized in the remaining 
experiments to prepare samples for the PicoGreen Assay. 
4.3.2 DNase Treatment Results 
 
Treatment with DNase was effective in reducing DNA content of the lyophilized Taxus 
culture by approximately 82% (Figure 18). This indicated that the process piloted is an effective 
way to remove a significant portion of the DNA in preparation of the delivery system. DNA 
removal would ultimately reduce the amount of foreign DNA being introduced into the body, 
which lowers the risk of adverse reactions to the treatment. Further optimization of this process 
regarding the concentration and activity of DNase could increase the amount of DNA degraded in 
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a sample. Product labels suggest using an alternative solvent to a phosphate buffer and avoiding 
agitation to increase efficacy [90]. 
DNA removal: 
 
Figure 18: Concentration of DNA (µg/mL) in solution after elicited (200 µM MeJA) and 
treated (20 mg/L PTX addition) lyophilized plant cells were treated with DNase (+DNase), 
incubated in buffer only (-DNase), and samples which were not treated (lyophilized 
biomass) and processed for DNA extraction. Error bars represent standard deviations of 
three biological samples which were each averaged from three technical replicates. 
DNA Staining 
Fluorescent DNA staining with Hoechst stain allowed for visualization and qualitative 
confirmation of DNA reduction after treatment with DNase (Figure 19). DNA containing nuclei 
are highlighted by the blue fluorescent punctates; remaining blue fluorescence was regarded as 
autofluorescence. Samples that were lyophilized or treated with buffer only showed similar 
exhibition of nuclei, while the sample treated with DNase show fewer nuclei. The nuclei that 
remain in the DNase+ sample (notably slide C) reaffirm the PicoGreen data that not all DNA is 
removed. Larger cellular aggregates made attaining clear images somewhat difficult. A method to 
break down aggregates before slide preparation or analyze a singer layer of cells may be useful to 
clarify results.  
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Figure 19: Images taken at 20x magnification of lyophilized 21260C (Taxus chinensis) 
culture elicited with MeJA and PTX displaying differences in DNA content between 
sample sets. DNA containing nuclei are highlighted by the blue fluorescent punctates, as 
indicated by the arrow in (Lyo. A). Treatments examined were DNase (DNase+), treatment 
with buffer only (DNase-), and lyophilized cells (Lyo). Each set of six images were from 
a single biological sample on the same microscope slide (A-C). Brightfield images are 
shown above fluorescent images in each treatment image group. 
DNA 
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Paclitaxel Quantification: 
 
Figure 20: Concentration of PTX (mg/L) in solution after lyophilized plant cells elicited 
with 200 µM MeJA and treated with a 20 mg/L PTX addition were treated with DNase 
(+DNase), incubated in buffer only (-DNase) and samples which were not treated 
(lyophilized) supernatants were collected after DNase treatment to determine the amount 
lost to the buffer during treatment. Error bars represent standard deviations of three 
biological samples that were each averaged from three technical replicates. 
 
The retention of PTX through the decellularization process is important to ensure that an 
adequate amount of PTX is retained for feasible treatment. Through the decellularization process 
a significant amount of the PTX is lost when compared to the lyophilized biomass (Figure 20). It 
is hypothesized the loss of PTX is attributed to the problem expressed in earlier experiments in 
which the PTX binds to water soluble proteins in the media and is therefore removed when washed 
with aqueous solutions. This observation is supported by the concentration of PTX found in the 
supernatant, which was removed directly after treatment, which accounts for a considerable 
amount of the PTX which is lost from the final biomass product. A complete mass balance was 
not achieved because the supernatants from all the wash steps were not processed. It is expected 
that if the quantity of PTX in the supernatant from each wash was summed, a greater convergence 
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to the original lyophilized product PTX concentration would be seen. A typical concentration of 
PTX for treatment by systemic delivery is 6 mg/mL which is then diluted to 0.2-1.2 mg/ml. This 
is presumably higher than would be required to be therapeutically significant in a localized 
delivery scenario because a majority of the drug would not be lost within the blood stream [97]. 
Further process optimization and better cell-associated PTX accumulation could produce a feasibly 
large concentration of PTX allowing for in vitro cell culture testing. 
4.3.3 Flavonoid and Phenolic Quantification 
 
Post-Lyophilization: 
Flavonoid and phenolic production increases under MeJA elicitation, and these metabolites 
have the potential for increased effectiveness of the drug delivery system through synergistic 
interactions with PTX. Retention of flavonoids and phenolics was quantified through the 
lyophilization process and wash step for all three conditions (Figure 20). 
 
Figure 21: Concentration (mg/mL) of flavonoids and phenolics in both elicited and 
unelicited (control) samples. Samples tested were: Total Culture (Pre Lyophilization), 
Lyophilized (Post Lyophilization), and Lyophilized and Washed (Post Wash). Error bars 
represent standard deviation amongst three biological replicates. 
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A significant concentration of both flavonoids and phenolics are lost during lyophilization 
and wash steps. Cells elicited with MeJA have larger observable concentrations of the metabolites 
compared to cells that have not been elicited. This difference becomes smaller after lyophilization, 
which could be due to the high volatility of the metabolites. Due to the potential for synergistic 
effects from these and other specialized metabolites, further optimization of the retention of 
flavonoids and phenolics and determination of their effect on system efficacy could prove 
beneficial for future work. 
Post-DNase Treatment: 
       
Figure 22: Concentration (mg/mL) of flavonoids and phenolics in +DNase (treated with 
DNase) -DNase (buffer only) and lyophilized biomass elicited samples. Error bars 
represent standard deviation amongst three biological replicates. 
 
Following treatment with DNase, the same trend as the post lyophilization analysis can be 
seen in which the use of an aqueous solution during treatment significantly decreases the 
concentration of flavonoids and phenolics in the delivery system. The interest in the synergistic 
effects due to the presence of these metabolites is not relevant unless an increase in the retention 
is achieved. Because PTX is also a specialized metabolite optimization of the process for retention 
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of PTX may also result in higher retention of theses metabolite; future studies should explore this 
possibility.  
4.3.4 Conclusions 
DNase treatment of lyophilized Taxus culture was successful in removing upwards of 80% 
of the DNA present in a sample within a 30-minute incubation period while maintaining a 
detectable amount of PTX despite a significant decrease in the concentration when compared to 
the initial lyophilized sample. The other specialize metabolites screened for (flavonoids and 
phenolics) were not maintained through the decellularization process. Overall, with proper 
optimization of PTX retention the decellularization process could be utilized to develop the drug 
delivery system. 
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Chapter 5: Drug Delivery System Effectiveness  
 
5.1 Background  
5.1.1. Current Treatment of Cancer with Paclitaxel 
PTX is an FDA-approved anticancer agent for several solid tumor types when 
accompanying neutrophil (white blood cell) counts are of at least 1000 cells/mm^3 [98]. It is 
administered as first-line treatment in non-small cell lung cancer and advanced ovarian carcinoma. 
In breast carcinoma and AIDS-Related Kaposi’s Sarcoma, it is administered as second line 
treatment [98]. The effectiveness of the PTX as an anticancer agent varies between cell line and 
cancer type, and it is sometimes administered concurrently with other chemotherapy drugs [98]. 
PTX is toxic to humans above a threshold concentration of 175 mg/m2 within 24 hours 
requiring proper dilution prior to delivery [99]. 
 The current solvent used in treatment today is composed of ethanol, Cremophor EL, and 
water [41]. This solvent is associated with anaphylactic hypersensitivity, an undesirable reaction 
characterized by labored breathing, rash, chest pain, low blood pressure, swelling of the deep 
dermis, and hives [37]. These devastating side effects drive the current push to develop drug 
delivery systems that meet the requirements to provide effective treatment while also minimizing 
undesirable side effects caused by the damage to healthy, surrounding cells. 
5.1.2. Simulating Paclitaxel Release Kinetics 
Drug release kinetics play a large role in the effective delivery of a drug. PTX is 
hydrophobic and has an affinity for proteins, such as human serum albumin (abundantly found in 
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the blood) in aqueous environments [100]. Measuring the release of PTX from decellularized 
Taxus biomaterial in a protein-rich solution can be used to preliminarily model how the DDS might 
release PTX in vivo.  
Drug stability over the expected length of time for delivery is essential to DDS efficacy. 
PTX has demonstrated variable stability dependent on temperature and solution composition, most 
commonly converting to 7-epi-taxol at higher temperatures, a thermodynamically more stable 
isomer [101].  Understanding PTX stability in the DDS and its release environment and release 
over time is important to maximize system efficacy and ensure that the patient receives a proper 
dose of drug.  
Nanoparticles are commonly used in the delivery of hydrophobic drugs and their release 
kinetics are commonly studied in vitro. Several methods used to study the release of drugs from 
nanoparticles include dialysis bag suspension, a steady flow through dialysis bag, and suspension 
in solvent [102]. Often, multiple release mediums are studied, such as PBS, PBS with surfactant, 
and PBS with protein [102]. One study quantified the release kinetics of PTX loaded poly(lactic-
co-glycolic acid) (PGLA) nanoparticles in various release mediums. Release studies such as these 
are intended to mimic release in vivo and are applicable to several DDSs. 
5.1.3. Drug and Tumor Interaction  
To create an effective drug delivery system, tumor pathology must also be considered. 
Tumors are not always of a single cell type and their composition is constantly changing. In 
conjunction with this, their surface marker phenotype may not be consistent across themselves or 
within subcultures [103]. Anti-cancer treatments are often not capable of penetrating tumor tissue 
which makes drug diffusion a concern [104]. There are several forms of direct injection that would 
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be desirable for a PTX total culture drug delivery system. These include microemulsions (mixtures 
of oil, water, and surfactant), hydrogels, and serums [73]. Examples include thermosensitive 
chitosan-based hydrogel that can be injected as a liquid to gel when heated to body temperature in 
order to control the local release of PTX over one month [44] as well as serums such as albumin 
which has been used in prior PTX studies [105]. 
 
5.2. Methodology 
5.2.1 Biomass Release Profile 
 
To determine the rate of release of PTX from the decellularized biomass, it was suspended 
in a PBS and bovine serum albumin (BSA) (Sigma-Aldrich, St Louis MO, 9048-46-8) solution. In 
triplicates, samples of decellularized biomass (procedure in Section 4.2.2) was suspended in 1 mL 
of 4% BSA-PBS solution (w:v) and degassed. Samples were incubated at 37 °C and shaken at 
approximately 150 RPM. Samples were taken 1, 6, 12, 24, 47, 72, 168 (7 days), and 480 (20 days) 
hours after initial suspension. During the sampling process, the sample tubes were centrifuged at 
15,000 RPM for 12-20 minutes until all biomass pelleted, and a 900 µL supernatant sample was 
removed and replaced with 900 µL of the 4% BSA in PBS solution. Samples were processed for 
UPLC using the method outlined in Section 3.2.4. 
5.2.2 Hydrogel Release Profile 
 
The alginate beads for PTX delivery were prepared using 1.5% (w:v) sodium alginate 
(Willpowder, Miami Beach FL) aqueous solution which was used to study two different 
conditions. One solution contained the decellularized biomass incorporated in a 2 mg/mL 
concentration while the other was loaded with PTX at a 6.85 mg/L concentration. The sodium 
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alginate and biomass mixture was added dropwise to a 10 mM calcium chloride (CaCl2) 
(Willpowder, Miami Beach FL) solution. After, the CaCl2 solution was removed to dry the beads. 
Beads were measured using a ruler as an in-picture scale and Microsoft PowerPoint was used to 
make size estimates. The average diameter was determined to be approximately 0.3-0.4 cm. 
The resulting microbeads were split evenly into 3 wells of a 6-well plate and suspended in 
4% BSA-PBS solution. In triplicate, each set of beads (biomass loaded and PTX loaded) were 
suspended in 5 mL of PBS containing 4% (w:v) of BSA protein and incubated at 37 °C and shaken 
on an incubator (New Brunswick Scientific Co. Inc, Edison NJ, G24 Environmental Incubator 
Shaker) at approximately 120 RPM. Samples were taken at 1, 6, and 12 hours until beads were 
degraded and no longer visible. At each time point 3.4 mL of solution were taken for sampling and 
the remaining liquid was discarded and replaced with 5 mL PBS-BSA solution. Samples taken 
were processed for UPLC using the method outlined in Section 3.2.4. 
5.2.3 Paclitaxel Degradation in Protein Solution 
PTX powder (0.4 mg) was dissolved in 10 mL of PBS containing 4% BSA (w:v) and 
incubated at 37 °C on a 120 RPM shaker. A well-mixed sample (1 mL) was taken immediately 
before incubation to confirm initial PTX concentration. Following incubation, two 0.5 mL samples 
were taken every 48 hours for one week. All samples were stored at -20 °C until UPLC processing 
using the method outlined in Section 3.2.4.  
5.3. Results 
5.3.1 Release Profile from Processed Biomass in BSA 
The acquired profile (Figure 22) for the decellularized drug delivery system indicates 
almost complete drug release from the biomass within 72 hours, with most of the PTX release 
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occurring in the first 24 hours. This establishes the feasibility of drug release to the intended site 
when placed in the body. Adjusting the initial concentration of PTX in the delivery system at 
implantation along with optimization of the drug release rate could prove to be an effective 
treatment for solid cancerous tumors. 
    
Figure 23: Mass of PTX (mg) released over time by samples after decellularized plant 
biomass is suspended in a 4 % BSA+PBS solution. F(A) Mass of PTX released (B) 
Accumulated PTX release. The mass of PTX in an initial sample is 0.00069 ± 0.00003496 
mg. Error bars represent standard deviations of three biological samples.  
5.3.2 Release Profile from Alginate in BSA 
 
   
Figure 24: Mass of PTX (mg) released over time by samples after decellularized plant 
biomass and free PTX were suspended in calcium alginate beads and suspended in a 4 % 
BSA+PBS solution. (A) Mass of PTX released (B) Accumulated PTX release. The mass 
of PTX in an initial sample is 0.00343 ± 0.0001748 mg. Error bars represent standard 
deviations of three biological samples.  
A B 
A B 
m = -9.6x10 -5 
m = -4.02x10 -5 
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Suspending the biomass in calcium alginate beads resulted in an observable difference in 
the how long the initial rate of release was sustained. Biomass encapsulated in calcium alginate 
sustained an almost consistent release rate over the first twelve hours (Figure 23). In comparison, 
the free biomass has two distinct slopes between the hour 1 - 6 and hour 6-12 (Figure 22). This is 
an indication that biomass encapsulated in alginate can sustain release longer than free biomass 
and avoid a spike in release typically associated with uncontrolled treatments.  
By comparing the release rate between the encapsulated biomass (biomass PTX) and free 
PTX by linear regression (Figure 23), the rate of release of free PTX is slower than that of biomass 
PTX. This could be attributed to a change in the diffusion coefficient of PTX with respect to 
microbead composition (Figure 24). Contact between biomass aggregates in the gel matrix could 
have resulted in a more porous structure of the beads, allowing for more diffusion of PTX and a 
higher diffusion coefficient. The study was not extended past 12 hours due to loss of structural 
integrity of the microbeads and subsequent homogenization with the PBS-BSA solution.  
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Figure 25: Visualization of alginate microbeads at hour 6 of release study. Biomass-PTX 
loaded alginate beads are shown on the left and free PTX microbeads on the right. Top 
images show microbeads submerged in BSA-PBS solution, while bottom images show the 
beads after solution was removed. 
5.3.3 Conclusions 
Overall, with proper optimization of preceding steps the drug delivery system has the 
capability to release PTX over time and thus has the potential for future development toward the 
goal of clinical applications. Further suspending the beads in a matrix hydrogel could increase the 
length of a sustained release rate for the which is desirable to increased control of drug dosage and 
length of treatment. Investigating this and other strategies for tuning PTX release will become 
imperative as this process develops further. 
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Chapter 6: Discussion 
This Major Qualifying Project studied the potential for use of processed suspension Taxus 
culture in a direct delivery system for PTX. Experiments were conducted to identify how the 
properties and contents changed throughout processing. Properties analyzed included 
concentration and retention of PTX, DNA, flavonoids, and phenolics in the cell-culture-product 
throughout processing. Additionally, the release of PTX from processed cell culture, and process 
cell culture suspended in alginate beads was studied. The following section outlines the results as 
well as an overview of future direction to build upon these results.   
 
6.1 Future Research 
6.1.1. Production and Retention of Cell Produced Paclitaxel 
Maximizing the amount of PTX retained through decellularization processing was a central 
consideration of this project. To determine fractional loss throughout processing steps, PTX was 
quantified at various points. PTX was initially introduced into the culture system through both 
natural production via elicitation with MeJA as well as direct addition of purified PTX to cultures. 
It was determined that the best method to gain an effective accumulation of PTX was through the 
use of cells which have both been elicited and treated with 20 mg/L PTX.  
For a suspension-culture derived delivery system to be feasible in industry, the cells will 
need to be able to produce and retain sufficient levels of PTX for treatments to be effective. 
Additionally, uniformity and quality control of the production process is essential before transition 
to commercial scale. Elicitors, such as MeJA could be further studied to better understand and 
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promote the biosynthesis of PTX. Further research on potential transport mechanisms of PTX 
could help to identify potential modes of efflux that could provide avenues to impact the 
intracellular accumulation and/or retention of PTX throughout processing steps.  
Further investigation of PTX production in suspension cultures could provide insight to 
methods that could increase the yield of PTX. Research done so far includes growth media tuning 
and elicitation agents [74]. Patented elicitation agents of taxanes include silver ions or complexes, 
jasmonic acids, auxin-related growth regulators, and phenylpropanoid pathway inhibitors [74]. 
Understanding the mechanisms by which these elicitation agents’ function could bring further 
insight to understanding the biosynthetic pathway of PTX and strategies to manipulate it. 
Additionally, media composition containing levels of taxane precursor(s) a or b-phenylalanine, 
amino acids, or and sufficient sugars (act as carbon source) promotes the biosynthesis of taxanes 
[74]. Modification of the environment that cultures are grown in could also be considered. For 
instance, environmental oxygen can affect the rate of specialized metabolite synthesis and oxygen 
demands are not constant, varying across growth phases and upon MeJA elicitation [74]. Along 
with the optimization of the growth environment itself, investigations into multi-stage culture have 
shown promising results regarding PTX and specialized metabolite production [106]. 
Phenolic, flavonoid, and related compounds can hinder the growth, vitality, and production 
of cells when present in abnormal concentrations in culture [74]. Some of the negative effects of 
high concentrations of these compounds may be reduced with low concentrations of antioxidant 
agents, such as ascorbic acid in the media (10 ppb - 10 ppm) [74]. Additionally, media 
replenishment strategies, such as a flow bioreactor or simple media replacement, may alleviate 
these issues. On the contrary, the properties of specialized metabolites in higher than average 
concentrations, such as those of phenolic compounds (anti-inflammatory, oxidative stress 
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protection, anti-bacterial, anti-parasitic, and antiseptic) could act synergistically when retained 
within the DDS [65]. The potential synergistic effects of these compounds with PTX are one area 
which further research could identify the benefits or challenges of a full-cell based DDS. 
6.1.2. Expansion of Specialized Metabolite Study 
This project only examined flavonoid and phenolic production and retention throughout 
processing. Our preliminary results found that elicitation with MeJA increases the concentration 
of both metabolite classes in culture, although concentrations were significantly reduced with DDS 
processing steps. Identification and quantification of specific metabolites is important to research 
further so that potential synergistic effects between the DDS and tissue can be anticipated, or even 
manipulated. Future research could be geared towards determining conditions that promote the 
production of favorable metabolites in Taxus as well as identifying techniques to retain those 
desired metabolites throughout processing, such as phenolic compounds with anti-inflammatory 
properties [65]. 
Numerous other specialized metabolites such as terpenoids and alkaloids, some of the most 
common metabolites produced, are also likely present in Taxus culture [107]. Alkaloids are of 
pharmaceutical interest primarily due to their pain reliving, anti-malarial, anti-cancer, anti-
inflammatory, anti-bacterial, anti-viral, and neurotoxic properties [65]. Although many of these 
properties could be beneficial, there is also many possible adverse reactions. Identifying 
compounds which could cause these and developing methods to remove or minimize their effects 
will be an important step in the further development of this project.  
6.1.3. Further Study of Decellularization Process 
 
DNA removal experiments used deoxyribonuclease I from bovine pancreas to digest DNA 
and the PicoGreen Assay to quantify the removal. Further research could be done on alternative 
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decellularization enzymes or methods that may allow for an increase retention of PTX or beneficial 
metabolites during the process. Further research into the ordering, number, and method of wash 
steps could be done to minimize PTX loss and make the process more efficient and scalable.  
6.1.4. Determination of Cytotoxicity in vitro 
 
It is common to use cytotoxicity against cancer cell lines to determine if the anticancer 
agent is effective [103]. There are a variety of assays that can be done to assess cytotoxicity and 
cell viability. The MTT assay is a colorimetric assay which uses a dye that is reduced by living 
cells and correlates the spectrophotometric absorbance to the amount of viable cells [108]. This 
assay, or comparable alternatives, can be performed on a cancer cell lines with various treatments 
to quantify cytotoxic effects of the DDS. The result of such tests would reflect the potential for the 
treatment to influence cancer in vivo [109].  
6.1.5. Interaction of DDS with Tissue 
The effectiveness of the DDS on tumors and biocompatibility of it with surrounding tissue 
is an important area of interest in this research that can be started with testing in-vitro. 
Biocompatibility of the DDS with healthy cells and with tumor cells should be investigated. 
Cytotoxicity and cell viability can be evaluated with assays such as the MTT, a colorimetric assay, 
and resazurin, a fluorometric assay [108, 109].  
The release of the PTX from the DDS could be refined with a variety of methods. For 
instance, an impermeable layer or film could be introduced to one side of the DDS to inhibit drug 
transfer away from the site of interest. An extended release system, such as through steady 
degradation of a polymer matrix, could also be employed. Achieving a therapeutically relevant 
drug concentration in the surrounding tissue over the desired time frame will require significant 
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tuning of the DDS. The rate of release could also be studied under various circumstances such as 
material composition modifications or in environments that more accurately mimic in vitro 
conditions such as 3D cultures [15]. 
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Appendix A. Raw Data 
A.1 Chapter 3 Data 
A.1.1 Inhibitor Experiment 
A.1.1a UPLC Data (Inhibitor Experiment) 
 
Table A1: UPLC area data for standards in inhibitor experiment. The average area of the standards 
was used to make the standard curve. Cycle letters represent the number of times the standard was 
run through the UPLC.  The slope of the standard curve was found to be 32074 with an R squared 
of 0.9855.  
      Cycle a b c d e f g  Average (a-g) 
PT
X
 S
ta
nd
ar
d 
0 mg/L 0 0 0 0 0 0   0 
12.5 
mg/L 530860 535400 344266   222506 221666   370940 
25 mg/L 950618 947453 857206   828078 819734 817343 880618 
50 mg/L 2044978 2037738 1689079 168963 1013865 1000873   1325916 
100 mg/L 3668206 3770754 3137480 3141435 3145018 3135128   3333004 
 
Table A2: UPLC data for inhibitor experiment samples from Day 14. Each inhibitor or treatment 
was done in replicates of three flask. Each flask had two total culture samples taken (C1 and C2) 
and two media samples taken (M1 and M2). Samples showing measurable PTX were indicated and 
used for results. Treatments showing no measurable PTX in any samples were omitted for clarity 
and brevity.  
Day 14 Samples 
  
Measurable 
Number Sample Time Area PTX? 
Standard STD 0 mg/L 14 
 
0 
 
Standard STD 12.5mg/L 14 3.535 530860 
 
Standard STD 25 mg/L 14 3.477 950618 
 
Standard STD 50 mg/L 14 3.405 2044978 
 
Standard STD 100 mg/L 14 3.37 3668206 
 
1 - 12 All Control Samples (Day 14) 
 
NO 
Standard STD 12.5 mg/L 3.334 535400 
 
13 MeJA 1 C1 3.327 43910 YES 
14 MeJA 1 C2 3.36 0 
 
15 MeJA 1 M1 3.362 0 
 
16 MeJA 1 M2 3.318 8275 YES 
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17 MeJA 2 C1 3.357 0 
 
18 MeJA 2 C2 3.355 0 
 
19 MeJA 2 M1 3.172 6255 YES 
20 MeJA 2 M2 3.172 4147 YES 
21 MeJA 3 C1 3.353 0 
 
22 MeJA 3 C2 3.408 0 
 
23 MeJA 3 M1 3.407 0 
 
24 MeJA 3 M2 3.409 0 
 
Standard STD 25 mg/L 3.326 947453 
 
25-36 All Verapamil Samples (Day 14) NO 
Standard STD 50 mg/L 14 3.31 2037738 
 
37 CY 1 C1 3.337 0 
 
38 CY 1 C2 3.332 0 
 
39 CY 1 M1 3.331 0 
 
40 CY 1 M2 3.332 0 
 
41 CY2 C1 3.308 0 
 
42 CY2 C2 3.299 0 
 
43 CY2 M1 3.328 0 
 
44 CY2 M2 3.262 0 
 
45 CY3 C1 3.21 1068 YES 
46 CY3 C2 
 
0 
 
47 CY3 M1 
 
0 
 
48 CY3 M2 
 
0 
 
Standard STD 100 mg/L 3.18 3770754 
 
Day 14 Samples Time Area Measurable 
PTX? 
Standard STD 100 mg/L 3.099 3141435 
 
49 VN1 C1 3.094 7377 YES 
50 VN 1 C2 3.1 0 
 
51 VN1 M1 3.1 0 
 
52 VN1 M2 3.1 0 
 
53 VN2 C1 3.114 0 
 
54 VN2 C2 3.111 0 
 
55 VN2 M1 ~3.1 0 
 
56 VN2 M2 ~3.111 0 
 
57 VN3 C1 3.107 0 
 
58 VN3 C2 3.102 0 
 
Standard STD 12.5 mg/L 3.079 344266 
 
59 VN3 M1 
 
0 
 
60 VN3 M2 
 
0 
 
61-68 All Vanadate & Verapamil Samples (Day 
14) 
NO 
Standard STD 25 mg/L 3.1 857206 
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69-72 All Vanadate & Verapamil Samples (Day 
14) 
NO 
 
Table A3: UPLC data for inhibitor experiment samples from Day 21 following the same layout as 
the Day 14 table.  
Day 21 Samples 
  
Measurable 
Number Sample Time Area PTX? 
73 Ctrl 1 C1 3.087 1325 YES 
74 CTRL 1 C2 3.075 1136 YES 
75 CTRL 1 M1 3.084 1384 YES 
76 CTRL 1 M2 3.088 1649 YES 
77 CTRL 2 C1 3.113 26262 YES 
78 CTRL 2 C2 3.108 40368 YES 
Standard STD 50 MG/ML 3.082 1689079   
79 CTRL 2 M1 3 12952 YES 
80 CTRL 2 M2 3.082 17940 YES 
81 CTRL 3 C1 3.042 962 YES 
82 CTRL 3 C2 3.04 785 YES 
83 CTRL 3 M1 3.04 0   
84 CTRL 3 M2 3.04 0   
85 MeJA 1 C1 3.042 447 YES 
86 MeJA 1 C2 3.042 685 YES 
87 MeJA 1 M1 3.039 894 YES 
88 MeJA 1 M2 3.041 1222 YES 
Standard STD 100 mg/L 3.053 3137480   
89 MeJA 2 C1 3.037 7250 YES 
90 MeJA 2 C2 3.037 2154 YES 
91 MeJA 2 M1 3.04 0   
92 MeJA 2 M2 3.04 0   
93 MeJA 3 C1 3.041 4763 YES 
94 MeJA 3 C2 2.974 44465 YES 
95 MeJA 3 M1 3.04 0   
96 MeJA 3 M2 3.04 0   
Standard STD 50 mg/L 3.051 168963   
Day 21 Samples   
Standard STD 0 mg/L 0 0   
Standard STD 12.5 mg/L 3.042 222506   
Standard STD 25 mg/L 3.043 828078   
Standard STD 50 mg/L 3.043 1013865   
Standard STD 100 mg/mL 3.041 3145018   
97 VP 1 C1 (21) 3.051 38488 YES 
98 VP 1 C2 3.052 767 YES 
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99 VP 1 M1 3.038 1957 YES 
100 VP1 M2 3.037 3847 YES 
101 VP2 C1 3.03 72415 YES 
102 VP2 C2 3.052 4510 YES 
103 VP2 M1 3.05 0   
104 VP2 M2 3.05 0   
105 VP3 C1 3.05 0   
106 VP3 C2 3.05 0   
Standard STD 12.5 mg/L 3.045 221666   
107 VP3 M1 3.045 0   
108 VP3 M2 3.027 5109 YES 
109 CY1 C1 3.045 0   
110 CY1 C2 3.045 0   
111 CY1 M1 3.045 0   
112 CY1 M2 3.045 0   
113 CY2 C1       
114 CY2 C2       
115 CY2 M1 3.028 5981 YES 
116 CY2 M2 3.032 3714 YES 
Standard STD 25 mg/L 3.038 819734   
117 CY3 C1 3.038 0   
118 CY3 C2 3.038 0   
119 CY3 M1 3.038 0   
120 CY3 M2 3.038 0   
 121 - 126  All Vanadate Samples (Day 21)   NO 
Standard STD 50 mg/L 2.985 1000873   
 127 - 132 All Vanadate Samples (Day 21)   NO 
 133 - 137 All Vanadate + Verapamil Samples (Day 21) NO 
Standard STD 100 mg/L 2.99 3135128   
 137-144 All Vanadate + Verapamil Samples (Day 21) NO 
Standard STD 25 mg/L 2.987 817343   
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A.1.1b Coulter Counter Data (Inhibitor Experiment) 
These tables show raw data collected from the Coulter Counter during the inhibitor experiments. 
The minimum and average bin diameters were set by the coulter counter system. In each sample, 
(a) represents the number of aggregates counted by the instrument that fall into the bin in the 
column and (b) represents the percent of aggregates of the total sample that fall into that bin size.  
On each day (Day 14 and Day 21), the same Coulter Counter parameters were used. The leftmost 
bin column is used as a label for each bin. 
 
Table A4: Coulter counter parameters compared to blanks on days 14 and 21. 
 Coulter Counter Parameters Blank Day 14 Blank Day 21 
Bin Min. Bin Avg. Bin Sample 1 Sample 2 Sample 1 Sample 2 
 Dia. (um) Dia. (um) a b a b a b a b 
1 72.3 74.38925 9 15.19 13 4.73 109 0.0034 4 3.7028 
2 76.4785 78.68845 1 2.06 9 3.997 49 0.0018 7 7.6696 
3 80.8984 83.2361 1 2.514 7 3.794 54 0.0024 4 5.1872 
4 85.5738 88.0466 3 9.203 6 3.968 39 0.002 7 10.744 
5 90.5194 93.1351 3 11.23 4 3.229 14 0.0009 4 7.2668 
6 95.7508 98.5179 0 0 5 4.926 22 0.0016 3 6.4507 
7 101.285 104.2115 2 11.15 5 6.011 12 0.001 1 2.545 
8 107.138 110.234 1 6.806 2 2.935 13 0.0013 1 3.0122 
9 113.33 116.605 2 16.61 3 5.372 3 0.0004 0 0 
10 119.88 123.344 1 10.14 0 0 10 0.0014 2 8.4396 
11 126.808 130.4725 0 0 2 5.334 4 0.0007 1 4.9946 
12 134.137 138.013 1 15.1 0 0 11 0.0022 2 11.823 
13 141.889 145.989 0 0 1 3.973 4 0.001 0 0 
14 150.089 154.426 0 0 0 0 8 0.0023 2 16.563 
15 158.763 163.351 0 0 2 11.83 1 0.0003 0 0 
16 167.939 172.792 0 0 1 7.222 0 0 1 11.601 
17 177.645 182.778 0 0 1 8.813 2 0.0009 0 0 
18 187.911 193.341 0 0 0 0 1 0.0006 0 0 
19 198.771 204.515 0 0 0 0 2 0.0013 0 0 
20 210.259 216.335 0 0 0 0 0 0 0 0 
21 222.411 228.8375 0 0 0 0 2 0.0018 0 0 
22 235.264 242.0625 0 0 1 23.86 0 0 0 0 
23 248.861 256.0525 0 0 0 0 3 0.0039 0 0 
24 263.244 270.8505 0 0 0 0 1 0.0015 0 0 
25 278.457 286.504 0 0 0 0 0 0 0 0 
26 294.551 303.0625 0 0 0 0 4 0.0085 0 0 
27 311.574 320.5775 0 0 0 0 5 0.0126 0 0 
28 329.581 339.1045 0 0 0 0 3 0.009 0 0 
29 348.628 358.702 0 0 0 0 3 0.0106 0 0 
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30 368.776 379.4325 0 0 0 0 3 0.0126 0 0 
31 390.089 401.3615 0 0 0 0 14 0.0695 0 0 
32 412.634 424.5575 0 0 0 0 15 0.0881 0 0 
33 436.481 449.094 0 0 0 0 23 0.1599 0 0 
34 461.707 475.049 0 0 0 0 14 0.1152 0 0 
35 488.391 502.504 0 0 0 0 15 0.1461 0 0 
36 516.617 531.5455 0 0 0 0 10 0.1153 0 0 
37 546.474 562.265 0 0 0 0 11 0.1501 0 0 
38 578.056 594.76 0 0 0 0 16 0.2584 0 0 
39 611.464 629.1335 0 0 0 0 27 0.5161 0 0 
40 646.803 665.4935 0 0 0 0 33 0.7466 0 0 
41 684.184 703.9545 0 0 0 0 31 0.8301 0 0 
42 723.725 744.638 0 0 0 0 17 0.5388 0 0 
43 765.551 787.673 0 0 0 0 37 1.388 0 0 
44 809.795 833.1955 0 0 0 0 70 3.108 0 0 
45 856.596 881.349 0 0 0 0 83 4.3617 0 0 
46 906.102 932.285 0 0 0 0 195 12.129 0 0 
47 958.468 986.164 0 0 0 0 468 34.453 0 0 
48 1013.86 1043.16 0 0 0 0 252 21.958 0 0 
49 1072.46 1103.45 0 0 0 0 104 10.726 0 0 
50 1134.44 1167.22 0 0 0 0 66 8.0563 0 0 
           
 
 
Table A5: Day 14 Coulter counter data: control and cyclosporine treatments. Flask three of the 
cyclosporine treatment encountered a processing error and data was not collected.  
 Control Day 14 Cyclosporine Day 14 
Bin Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 
 a b a b a b a b a b 
 370 0.268 160 0.121 975 0.626 63 0.049 62 0.07 
1 318 0.281 142 0.131 664 0.52 29 0.028 34 0.047 
2 307 0.331 133 0.15 520 0.497 45 0.053 37 0.062 
3 301 0.396 132 0.182 453 0.529 51 0.073 31 0.064 
4 310 0.498 107 0.18 438 0.624 49 0.085 33 0.083 
5 260 0.509 123 0.252 444 0.772 38 0.081 33 0.101 
6 274 0.655 142 0.355 454 0.963 47 0.122 34 0.127 
7 237 0.692 146 0.445 373 0.966 58 0.183 45 0.205 
8 242 0.862 147 0.547 155 0.49 51 0.197 42 0.234 
9 234 1.017 137 0.623 117 0.451 46 0.217 33 0.224 
10 207 1.098 133 0.738 125 0.588 41 0.236 48 0.398 
11 205 1.327 113 0.765 125 0.718 51 0.358 33 0.334 
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12 180 1.422 139 1.148 96 0.673 62 0.531 39 0.481 
13 177 1.707 124 1.25 102 0.872 40 0.418 30 0.452 
14 162 1.907 112 1.378 95 0.992 46 0.586 35 0.643 
15 139 1.997 96 1.442 79 1.006 42 0.653 28 0.628 
16 99 1.736 119 2.181 79 1.228 40 0.759 26 0.712 
17 93 1.99 88 1.968 90 1.708 42 0.973 24 0.802 
18 103 2.689 101 2.757 66 1.528 45 1.272 25 1.02 
19 86 2.741 77 2.565 72 2.035 42 1.449 36 1.792 
20 67 2.606 78 3.171 47 1.621 23 0.969 28 1.701 
21 50 2.373 50 2.481 47 1.979 35 1.799 16 1.186 
22 47 2.723 38 2.301 45 2.312 41 2.572 23 2.081 
23 48 3.393 39 2.882 39 2.445 26 1.99 17 1.877 
24 34 2.933 36 3.247 40 3.061 20 1.869 14 1.887 
25 49 5.16 38 4.183 35 3.269 15 1.71 14 2.303 
26 34 4.369 29 3.896 25 2.849 16 2.226 16 3.212 
27 30 4.705 18 2.951 24 3.339 20 3.397 26 6.37 
28 33 6.316 29 5.803 28 4.753 17 3.523 7 2.093 
29 21 4.906 21 5.129 19 3.937 25 6.324 11 4.014 
30 19 5.417 23 6.855 18 4.551 20 6.174 8 3.563 
31 13 4.523 17 6.184 16 4.938 12 4.521 11 5.978 
32 14 5.945 11 4.883 21 7.909 8 3.678 5 3.317 
33 5 2.591 6 3.251 14 6.435 13 7.295 4 3.238 
34 5 3.162 5 3.306 14 7.853 9 6.164 6 5.928 
35 6 4.631 8 6.456 9 6.162 6 5.015 10 12.06 
36 5 4.71 4 3.939 4 3.342 6 6.12 5 7.358 
37 2 2.299 1 1.202 4 4.079 2 2.49 3 5.388 
38 1 1.403 2 2.934 2 2.489 0 0 4 8.767 
39 1 1.712 2 3.581 2 3.038 5 9.271 1 2.675 
40 0 0 1 2.185 1 1.854 3 6.789 2 6.529 
41 0 0 0 0 0 0 1 2.762 0 0 
42 0 0 0 0 0 0 0 0 0 0 
43 0 0 0 0 0 0 0 0 0 0 
44 0 0 0 0 0 0 1 5.02 0 0 
45 0 0 0 0 0 0 0 0 0 0 
46 0 0 0 0 0 0 0 0 0 0 
47 0 0 0 0 0 0 0 0 0 0 
48 0 0 0 0 0 0 0 0 0 0 
49 0 0 0 0 0 0 0 0 0 0 
50           
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Table A6: Day 14 Coulter counter data: elicited and vanadate treatments. 
 Elicited Day 14 Vanadate Day 14 
Bin Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
 a b a b a b a b a b a b 
1 37 0.021 144 0.101 27 0.137 68 0.039 51 0.037 62 0.121 
2 36 0.025 102 0.088 24 0.149 67 0.047 35 0.031 36 0.085 
3 38 0.032 92 0.097 29 0.22 65 0.056 31 0.033 20 0.058 
4 37 0.038 118 0.151 27 0.25 68 0.072 37 0.048 22 0.078 
5 47 0.059 49 0.077 23 0.26 51 0.065 47 0.075 29 0.125 
6 55 0.084 33 0.063 21 0.289 59 0.092 46 0.089 32 0.169 
7 41 0.077 40 0.093 25 0.421 68 0.13 43 0.102 33 0.212 
8 43 0.098 28 0.08 20 0.411 58 0.135 55 0.159 30 0.235 
9 42 0.117 50 0.173 26 0.651 61 0.174 56 0.198 23 0.22 
10 44 0.15 35 0.148 35 1.07 47 0.163 38 0.164 30 0.351 
11 42 0.175 54 0.279 20 0.746 64 0.272 46 0.242 40 0.57 
12 49 0.249 49 0.309 18 0.82 55 0.285 41 0.263 32 0.557 
13 46 0.285 43 0.331 23 1.278 73 0.461 47 0.368 33 0.701 
14 52 0.393 57 0.535 25 1.696 54 0.417 53 0.506 32 0.83 
15 36 0.332 54 0.619 19 1.573 67 0.631 41 0.478 34 1.076 
16 47 0.529 48 0.671 23 2.324 68 0.781 54 0.768 29 1.12 
17 39 0.536 46 0.785 10 1.233 66 0.925 53 0.921 27 1.272 
18 63 1.056 58 1.208 20 3.01 55 0.941 49 1.039 26 1.495 
19 45 0.921 53 1.348 16 2.939 45 0.94 37 0.957 26 1.825 
20 45 1.124 43 1.334 5 1.121 62 1.58 45 1.421 24 2.056 
21 41 1.25 34 1.288 10 2.736 62 1.929 41 1.58 10 1.045 
22 28 1.042 29 1.34 6 2.003 51 1.936 36 1.693 12 1.531 
23 29 1.317 30 1.692 8 3.26 38 1.761 31 1.779 14 2.18 
24 26 1.441 26 1.79 4 1.989 39 2.205 28 1.961 12 2.28 
25 17 1.15 32 2.689 9 5.462 41 2.829 24 2.051 11 2.551 
26 23 1.898 30 3.076 8 5.925 27 2.274 24 2.504 12 3.397 
27 22 2.216 16 2.002 2 1.808 32 3.289 23 2.928 8 2.764 
28 18 2.213 24 3.666 3 3.31 31 3.889 19 2.952 10 4.216 
29 15 2.25 18 3.355 5 6.732 19 2.909 16 3.034 4 2.058 
30 17 3.112 21 4.777 3 4.929 26 4.858 18 4.166 5 3.14 
31 14 3.128 16 4.442 1 2.005 22 5.016 12 3.389 5 3.832 
32 19 5.181 19 6.438 1 2.447 9 2.505 15 5.171 4 3.741 
33 11 3.661 12 4.962 2 5.974 19 6.453 11 4.628 6 6.849 
34 10 4.062 11 5.552 0 0 19 7.875 9 4.621 2 2.786 
35 12 5.948 13 8.007 2 8.898 16 8.094 4 2.506 6 10.2 
36 7 4.235 4 3.007 1 5.429 10 6.174 9 6.883 2 4.15 
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37 14 10.34 6 5.505 1 6.626 5 3.767 7 6.533 1 2.532 
38 13 11.71 7 7.838 0 0 7 6.437 3 3.417 4 12.36 
39 9 9.897 6 8.199 1 9.869 6 6.733 6 8.341 1 3.772 
40 8 10.74 2 3.335 0 0 4 5.478 3 5.09 1 4.603 
41 3 4.914 0 0 0 0 2 3.343 3 6.212 0 0 
42 1 1.999 1 2.484 0 0 1 2.04 3 7.581 1 6.856 
43 0 0 2 6.063 0 0 0 0 1 3.084 0 0 
44 0 0 0 0 0 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 0 0 0 0 0 
46 0 0 0 0 0 0 0 0 0 0 0 0 
47 0 0 0 0 0 0 0 0 0 0 0 0 
48 0 0 0 0 0 0 0 0 0 0 0 0 
49 0 0 0 0 0 0 0 0 0 0 0 0 
50 0 0 0 0 0 0 0 0 0 0 0 0 
             
 
Table A7: Day 14 Coulter counter data: verapamil and combined (vanadate & verapamil) 
treatments. 
 Verapamil Day 14 Vanadate and Verapamil Day 14 
Bin Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
 a b a b a b a b a b a b 
1 57 0.118 231 0.246 50 0.056 102 0.035 44 0.034 162 0.201 
2 40 0.101 120 0.156 51 0.07 90 0.037 39 0.037 101 0.153 
3 42 0.129 63 0.1 40 0.067 59 0.03 27 0.031 87 0.161 
4 37 0.139 65 0.126 35 0.072 61 0.038 36 0.051 88 0.199 
5 27 0.124 61 0.144 49 0.122 77 0.058 46 0.079 72 0.198 
6 39 0.218 65 0.188 38 0.116 77 0.071 33 0.069 91 0.306 
7 31 0.211 65 0.229 36 0.134 61 0.068 30 0.077 79 0.324 
8 34 0.283 51 0.219 40 0.181 65 0.089 39 0.122 87 0.436 
9 26 0.264 74 0.388 35 0.194 69 0.115 36 0.137 72 0.44 
10 38 0.471 57 0.365 42 0.284 79 0.161 37 0.172 64 0.478 
11 32 0.484 56 0.438 43 0.355 81 0.202 40 0.227 81 0.738 
12 22 0.406 44 0.42 45 0.453 79 0.24 39 0.27 66 0.734 
13 35 0.788 62 0.722 43 0.528 82 0.304 46 0.388 66 0.895 
14 44 1.21 65 0.924 37 0.555 65 0.294 39 0.401 66 1.093 
15 28 0.94 66 1.145 26 0.476 87 0.481 40 0.503 45 0.909 
16 34 1.392 69 1.46 30 0.67 72 0.486 50 0.767 42 1.036 
17 37 1.849 54 1.395 24 0.654 82 0.675 46 0.861 63 1.896 
18 33 2.013 57 1.797 26 0.864 67 0.673 47 1.073 47 1.726 
19 26 1.935 41 1.577 31 1.258 74 0.907 39 1.087 40 1.793 
20 29 2.635 35 1.643 32 1.585 102 1.526 46 1.565 39 2.133 
21 26 2.883 34 1.948 18 1.088 64 1.169 25 1.038 36 2.403 
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22 18 2.436 36 2.518 15 1.106 52 1.159 22 1.115 28 2.281 
23 20 3.303 23 1.963 17 1.53 67 1.822 26 1.608 29 2.884 
24 23 4.636 12 1.25 8 0.879 54 1.792 12 0.906 22 2.67 
25 12 2.952 11 1.398 5 0.67 60 2.43 24 2.21 19 2.814 
26 5 1.501 16 2.483 11 1.8 46 2.274 31 3.484 11 1.988 
27 10 3.664 14 2.651 10 1.997 37 2.232 20 2.743 15 3.309 
28 12 5.365 16 3.698 11 2.681 31 2.283 26 4.353 10 2.692 
29 7 3.82 12 3.385 9 2.677 37 3.325 18 3.678 6 1.971 
30 10 6.66 12 4.131 8 2.904 29 3.181 22 5.486 8 3.208 
31 7 5.689 12 5.041 9 3.987 27 3.614 12 3.652 14 6.852 
32 8 7.935 8 4.102 1 0.541 26 4.247 15 5.571 11 6.57 
33 4 4.842 12 7.508 4 2.64 24 4.785 8 3.626 7 5.103 
34 4 5.91 4 3.055 2 1.611 33 8.029 8 4.425 4 3.559 
35 3 5.409 9 8.388 4 3.931 18 5.345 8 5.401 4 4.343 
36 3 6.602 7 7.962 6 7.197 14 5.074 4 3.296 6 7.95 
37 1 2.686 5 6.941 4 5.856 9 3.981 1 1.006 2 3.234 
38 0 0 2 3.388 2 3.573 15 8.097 7 8.59 2 3.947 
39 2 8 1 2.068 5 10.9 7 4.611 8 11.98 2 4.817 
40 0 0 1 2.523 3 7.983 4 3.216 1 1.828 0 0 
41 0 0 2 6.159 4 12.99 4 3.925 2 4.462 2 7.175 
42 0 0 1 3.758 2 7.927 6 7.185 0 0 1 4.378 
43 0 0 0 0 1 4.837 3 4.384 2 6.645 0 0 
44 0 0 0 0 0 0 3 5.351 0 0 0 0 
45 0 0 0 0 0 0 0 0 1 4.949 0 0 
46 0 0 0 0 0 0 0 0 0 0 0 0 
47 0 0 0 0 0 0 0 0 0 0 0 0 
48 0 0 0 0 0 0 0 0 0 0 0 0 
49 0 0 0 0 0 0 0 0 0 0 0 0 
50 0 0 0 0 0 0 0 0 0 0 0 0 
             
 
Table A8: Day 21 Coulter counter data: control and cyclosporine treatments.  
 Control Day 21 Cyclosporine Day 21 
 Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
Bin a b a b a b a b a b a b 
1 850 0.7484 321 0.213 1527 1.2866 154 0.0891 61 0.1012 62 0.2386 
2 776 0.8087 301 0.2364 1044 1.0411 134 0.0918 61 0.1198 56 0.2551 
3 734 0.9054 273 0.2537 760 0.8971 144 0.1168 62 0.1441 69 0.372 
4 727 1.0614 300 0.33 575 0.8033 123 0.118 68 0.187 53 0.3382 
5 637 1.1007 275 0.358 564 0.9326 101 0.1147 55 0.1791 43 0.3248 
6 574 1.1739 296 0.4561 521 1.0197 118 0.1586 49 0.1888 42 0.3755 
7 546 1.3217 274 0.4998 466 1.0795 129 0.2053 46 0.2098 38 0.4021 
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8 485 1.3896 283 0.6109 367 1.0062 104 0.1959 31 0.1673 49 0.6136 
9 446 1.5124 233 0.5954 290 0.9411 105 0.2341 39 0.2492 44 0.6522 
10 388 1.5573 223 0.6744 270 1.037 111 0.2929 43 0.3252 47 0.8245 
11 332 1.5772 218 0.7803 193 0.8774 87 0.2717 52 0.4654 27 0.5606 
12 320 1.7993 185 0.7838 229 1.2322 90 0.3326 35 0.3708 35 0.8602 
13 321 2.1363 208 1.043 219 1.3947 100 0.4375 29 0.3636 37 1.0763 
14 242 1.9062 163 0.9674 185 1.3945 76 0.3935 40 0.5936 36 1.2395 
15 233 2.1723 147 1.0327 167 1.4899 57 0.3493 31 0.5445 26 1.0595 
16 196 2.1628 147 1.2222 160 1.6895 73 0.5295 29 0.6029 29 1.3987 
17 187 2.4423 127 1.2498 128 1.5998 80 0.6868 24 0.5906 27 1.5413 
18 149 2.3033 102 1.1881 130 1.923 66 0.6707 29 0.8446 25 1.6892 
19 148 2.7079 88 1.2132 108 1.8909 69 0.8299 26 0.8963 23 1.8394 
20 124 2.6853 87 1.4196 95 1.9687 55 0.7829 22 0.8976 17 1.6091 
21 89 2.2812 73 1.4099 91 2.232 53 0.893 26 1.2556 25 2.8008 
22 89 2.7 71 1.623 75 2.1773 43 0.8575 15 0.8574 14 1.8564 
23 74 2.6571 44 1.1904 63 2.1647 50 1.1802 17 1.1501 12 1.8834 
24 74 3.1449 39 1.2489 78 3.1722 42 1.1733 18 1.4413 15 2.7864 
25 53 2.666 33 1.2508 57 2.7437 45 1.488 11 1.0425 12 2.6384 
26 33 1.9647 39 1.7496 42 2.3929 31 1.2132 14 1.5704 14 3.6432 
27 44 3.1005 30 1.5929 40 2.6973 31 1.436 7 0.9294 9 2.7721 
28 43 3.5864 24 1.5083 40 3.1925 27 1.4803 9 1.4143 7 2.5519 
29 42 4.1461 25 1.8596 33 3.1174 27 1.7521 6 1.1159 2 0.863 
30 29 3.3884 26 2.289 29 3.2425 20 1.5361 10 2.2014 4 2.0428 
31 43 5.9465 18 1.8756 21 2.7791 24 2.1817 11 2.8661 8 4.8357 
32 21 3.4373 23 2.8367 28 4.3857 31 3.3355 8 2.4671 4 2.8618 
33 26 5.037 11 1.6057 18 3.337 15 1.9102 2 0.73 5 4.2339 
34 15 3.4395 17 2.9372 19 4.1691 26 3.919 10 4.3202 2 2.0045 
35 11 2.9854 14 2.863 16 4.1554 26 4.6385 5 2.5567 2 2.3725 
36 17 5.4608 20 4.8408 21 6.4552 22 4.6454 5 3.0261 3 4.2122 
37 12 4.5624 10 2.8648 10 3.6383 6 1.4995 4 2.8653 4 6.6473 
38 8 3.6 7 2.3735 9 3.8756 23 6.8036 2 1.6957 0 0 
39 1 0.5326 11 4.4146 10 5.0968 12 4.2014 3 3.0105 2 4.6561 
40 3 1.8912 9 4.2751 5 3.0163 13 5.3871 1 1.1877 2 5.5109 
41 0 0 2 1.1244 2 1.428 10 4.9048 3 4.2174 0 0 
42 0 0 4 2.6617 0 0 9 5.2247 2 3.3278 3 11.58 
43 0 0 1 0.7876 1 1.0003 8 5.4968 2 3.9387 1 4.5688 
44 0 0 6 5.5932 2 2.3678 6 4.8795 3 6.9928 1 5.4076 
45 0 0 2 2.2067 0 0 7 6.7379 3 8.2766 0 0 
46 0 0 5 6.5296 1 1.6585 4 4.5571 2 6.5307 0 0 
47 0 0 4 6.1827 0 0 3 4.0453 0 0 0 0 
48 0 0 3 5.4884 0 0 1 1.596 2 9.1489 0 0 
49 0 0 0 0 0 0 1 1.889 1 5.4143 0 0 
50 0 0 3 7.6886 0 0 1 2.2358 1 6.4083 0 0 
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Table A9: Day 21 Coulter counter data: elicited and vanadate treatments.  
 Elicited Day 21 Vanadate Day 21 
Bin Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
 a b a b a b a b a b a b 
1 210 0.3197 129 0.2426 36 0.1424 125 0.0592 158 0.0645 36 0.1207 
2 191 0.3441 93 0.207 30 0.1404 131 0.0735 125 0.0604 41 0.1627 
3 173 0.3689 111 0.2924 20 0.1108 106 0.0704 125 0.0715 34 0.1597 
4 166 0.419 91 0.2838 21 0.1377 100 0.0786 104 0.0704 35 0.1945 
5 147 0.4392 81 0.2989 22 0.1707 77 0.0716 108 0.0865 32 0.2105 
6 133 0.4703 73 0.3189 27 0.248 73 0.0804 108 0.1024 42 0.327 
7 129 0.5399 80 0.4136 31 0.3371 88 0.1147 106 0.119 39 0.3594 
8 108 0.535 90 0.5508 26 0.3346 72 0.111 105 0.1395 34 0.3709 
9 93 0.5453 71 0.5142 31 0.4722 64 0.1168 92 0.1447 33 0.4261 
10 105 0.7286 50 0.4286 25 0.4507 67 0.1447 80 0.1489 44 0.6724 
11 81 0.6653 63 0.6392 22 0.4694 41 0.1048 106 0.2335 35 0.6331 
12 75 0.7291 61 0.7326 31 0.7829 65 0.1967 87 0.2269 33 0.7065 
13 65 0.7479 67 0.9524 25 0.7473 65 0.2328 94 0.2901 32 0.8108 
14 71 0.9669 56 0.9421 37 1.3091 64 0.2713 82 0.2995 31 0.9297 
15 61 0.9833 52 1.0355 29 1.2144 54 0.271 96 0.4151 48 1.7038 
16 56 1.0684 43 1.0135 27 1.3382 52 0.3088 87 0.4452 36 1.5125 
17 54 1.2194 47 1.3111 33 1.9359 59 0.4147 87 0.5269 19 0.9448 
18 53 1.4165 39 1.2877 27 1.8747 49 0.4077 83 0.595 34 2.0011 
19 27 0.8541 26 1.0161 27 2.2189 51 0.5022 72 0.6109 28 1.9505 
20 48 1.7972 32 1.4801 22 2.1399 53 0.6177 60 0.6026 29 2.3911 
21 34 1.5067 38 2.0803 26 2.9933 55 0.7587 60 0.7132 26 2.5373 
22 25 1.3113 26 1.6847 17 2.3165 60 0.9797 68 0.9567 24 2.7721 
23 21 1.3037 26 1.994 21 3.3869 50 0.9663 63 1.0491 19 2.5975 
24 27 1.9839 25 2.2693 13 2.4816 45 1.0293 75 1.4782 12 1.9417 
25 25 2.1742 21 2.2562 11 2.4853 39 1.0559 41 0.9564 12 2.2982 
26 14 1.4411 11 1.3988 10 2.6742 27 0.8652 36 0.9939 9 2.0401 
27 16 1.9494 23 3.4617 6 1.8991 31 1.1757 42 1.3725 7 1.8781 
28 16 2.3072 11 1.9596 9 3.3716 25 1.1223 41 1.5858 8 2.5404 
29 11 1.8775 15 3.1627 4 1.7736 35 1.8596 34 1.5565 5 1.8793 
30 12 2.4242 13 3.2442 6 3.1488 35 2.201 36 1.9506 5 2.2243 
31 10 2.391 13 3.8399 2 1.2423 33 2.4562 43 2.7577 7 3.6857 
32 14 3.962 4 1.3984 4 2.9408 12 1.0572 29 2.2013 2 1.2464 
33 8 2.6796 8 3.3103 2 1.7403 26 2.711 25 2.2461 4 2.9505 
34 10 3.9645 7 3.4283 7 7.2095 15 1.8512 20 2.1267 6 5.2382 
35 7 3.2847 10 5.7967 7 8.5331 18 2.6293 21 2.643 4 4.1333 
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36 6 3.3323 5 3.4305 6 8.6569 17 2.9391 22 3.2773 2 2.4461 
37 8 5.2588 3 2.4362 0 0 19 3.888 18 3.1737 0 0 
38 2 1.5561 5 4.8057 3 6.0637 17 4.1174 13 2.7129 2 3.4267 
39 4 3.6835 3 3.4128 0 0 19 5.4467 13 3.211 4 8.1116 
40 3 3.2698 8 10.772 3 8.4946 17 5.7681 8 2.3388 2 4.8004 
41 4 5.1602 4 6.3747 1 3.3514 7 2.8111 7 2.4221 2 5.6817 
42 9 13.742 2 3.7725 1 3.9667 5 2.3766 12 4.9146 1 3.3624 
43 2 3.6144 2 4.4651 1 4.6949 13 7.3136 12 5.8168 0 0 
44 1 2.139 2 5.2849 0 0 4 2.6635 7 4.0161 0 0 
45 1 2.5317 0 0 0 0 5 3.9406 11 7.4697 0 0 
46 2 5.9931 0 0 0 0 3 2.7985 3 2.4112 0 0 
47 0 0 0 0 0 0 10 11.041 7 6.6591 2 15.621 
48 0 0 0 0 0 0 5 6.5339 8 9.0076 0 0 
49 0 0 0 0 0 0 5 7.7335 6 7.996 0 0 
50 0 0 0 0 0 0 2 3.6613 3 4.732 0 0 
 
            
             
 
Table A10: Day 21 Coulter counter data: verapamil and combined (vanadate and verapamil) 
treatments.  
 Verapamil Day 21 Vanadate and Verapamil Day 21 
Bin Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
 a b a b a b a b a b a b 
1 209 0.1006 110 0.1001 162 0.1219 52 0.0564 156 0.0653 49 0.06 
2 178 0.1014 112 0.1207 130 0.1158 44 0.0565 146 0.0723 50 0.072 
3 159 0.1072 121 0.1543 117 0.1234 32 0.0487 129 0.0756 44 0.075 
4 161 0.1285 93 0.1404 91 0.1136 35 0.063 110 0.0763 55 0.111 
5 119 0.1124 96 0.1715 100 0.1477 35 0.0746 123 0.101 51 0.122 
6 121 0.1353 111 0.2347 89 0.1556 47 0.1185 132 0.1283 49 0.139 
7 142 0.1879 102 0.2552 86 0.178 40 0.1194 113 0.13 56 0.188 
8 112 0.1754 113 0.3347 95 0.2327 36 0.1272 128 0.1743 56 0.223 
9 103 0.1909 93 0.326 93 0.2696 32 0.1338 127 0.2047 58 0.273 
10 114 0.2501 104 0.4315 72 0.247 32 0.1583 99 0.1888 54 0.301 
11 117 0.3038 96 0.4715 55 0.2233 34 0.1991 108 0.2438 37 0.244 
12 94 0.2889 84 0.4883 70 0.3364 51 0.3535 111 0.2966 52 0.406 
13 100 0.3638 82 0.5641 52 0.2958 30 0.2461 107 0.3384 48 0.443 
14 80 0.3444 80 0.6514 64 0.4309 39 0.3787 74 0.277 74 0.809 
15 96 0.4892 83 0.7999 62 0.4941 30 0.3448 81 0.3589 58 0.75 
16 79 0.4765 84 0.9582 71 0.6697 26 0.3537 77 0.4038 62 0.949 
17 93 0.6639 64 0.8641 48 0.5359 31 0.4991 73 0.4531 54 0.978 
18 81 0.6844 71 1.1346 40 0.5286 41 0.7813 82 0.6024 49 1.051 
19 86 0.86 74 1.3997 53 0.8289 33 0.7443 64 0.5565 39 0.99 
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20 72 0.8522 61 1.3656 52 0.9626 29 0.7742 79 0.8131 38 1.141 
21 74 1.0367 63 1.6693 44 0.964 36 1.1375 78 0.9502 28 0.995 
22 58 0.9617 56 1.7562 37 0.9595 27 1.0098 66 0.9516 36 1.515 
23 68 1.3346 60 2.2272 44 1.3505 22 0.9739 56 0.9556 44 2.191 
24 65 1.5099 49 2.1528 20 0.7266 26 1.3622 66 1.3331 33 1.945 
25 57 1.5671 32 1.664 24 1.032 22 1.3643 49 1.1714 22 1.535 
26 42 1.3667 36 2.2157 23 1.1705 21 1.5413 45 1.2733 24 1.982 
27 35 1.3481 32 2.3311 20 1.2047 20 1.7374 52 1.7415 17 1.662 
28 35 1.5956 30 2.5866 13 0.9268 11 1.131 54 2.1405 19 2.198 
29 38 2.0504 25 2.5513 26 2.194 19 2.3123 33 1.5482 20 2.739 
30 39 2.4906 20 2.4157 10 0.9988 19 2.7368 38 2.1101 12 1.945 
31 33 2.4944 21 3.0022 19 2.2461 8 1.3639 27 1.7746 11 2.11 
32 29 2.5945 10 1.6921 11 1.5391 8 1.6143 36 2.8005 12 2.725 
33 41 4.3415 14 2.8038 16 2.6497 8 1.9107 29 2.6701 7 1.881 
34 30 3.7599 8 1.8963 11 2.1561 8 2.2615 29 3.1603 12 3.817 
35 28 4.1535 12 3.3667 9 2.088 9 3.0112 20 2.5797 4 1.506 
36 16 2.8092 9 2.9886 11 3.0205 8 3.1681 23 3.5113 8 3.565 
37 23 4.7796 9 3.5373 9 2.925 11 5.1558 17 3.0718 7 3.692 
38 22 5.4112 10 4.652 8 3.0774 6 3.3286 16 3.4219 6 3.745 
39 23 6.6957 6 3.3036 6 2.7318 4 2.6265 11 2.7845 4 2.955 
40 19 6.5468 11 7.1686 8 4.3111 4 3.1087 12 3.5953 5 4.372 
41 14 5.7096 5 3.8567 5 3.1891 1 0.9198 12 4.2554 1 1.035 
42 16 7.7232 2 1.8259 4 3.0197 2 2.1775 13 5.4563 2 2.45 
43 7 3.9993 3 3.2417 4 3.5741 4 5.1544 5 2.4839 0 0 
44 5 3.3811 4 5.1158 8 8.4605 7 10.676 9 5.2918 1 1.716 
45 5 4.0018 1 1.5138 5 6.2586 3 5.4156 9 6.2634 2 4.062 
46 2 1.8946 3 5.375 1 1.4815 3 6.4099 5 4.1185 4 9.616 
47 4 4.4849 1 2.1206 2 3.5071 3 7.5867 4 3.8997 4 11.38 
48 0 0 0 0 3 6.2264 3 8.9796 3 3.4617 1 3.368 
49 2 3.1414 1 2.9707 3 7.3695 0 0 2 2.7315 2 7.972 
50 0 0 2 7.0323 4 11.63 1 4.1931 8 12.932 0 0 
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A.1.2 Paclitaxel Loading and Taxus Processing Experiments 
A.1.2a Mass Data (Loading and Processing Experiments) 
 
Table A11: Pre-Processing Mass Retention experiment. This table shows the masses of each 
sample at every point along the pre-processing steps. The same samples were analyzed for PTX 
concentration (Table B12).  
Sample Sample 
Weight 
Lyophilized 
Weight 
Washed 
 Weight 
Evaporated 
Weight 
Identifier g g g g 
PTX 0 S1 0.9697 
  
0.02 
PTX 0 S2 1.0286 
  
0.03 
PTX 0 S3 1.0295 
  
0.0313 
PTX 0 L1 1.0219 0.0294 
 
0.0281 
PTX 0 L2 1.0075 0.0284 
 
0.027 
PTX 0 L3 1.0061 0.029 
 
0.0277 
PTX 0 
L+W1 
1.0252 0.0347 0.0032 0.007 
PTX 0 
L+W2 
0.9443 0.0305 0.0395 0.0037 
PTX 0 
L+W3 
1.0293 0.0327 0.018 0.0056 
PTX 2 S1 1.0072 
  
0.0314 
PTX 2 S2 1.0392 
  
0.0297 
PTX 2 S3 0.9994 
  
0.0316 
PTX 2 L1 1.0098 0.0293 
 
0.0272 
PTX 2 L2 0.9269 0.0325 
 
0.0302 
PTX 2 L3 0.9164 0.0271 
 
0.0252 
PTX 2 
L+W1 
1.0296 0.0288 0.0647 0.0015 
PTX 2 
L+W2 
1.0308 0.032 0.1183 0.0039 
PTX 2 
L+W3 
0.9862 0.03 0.0823 0.003 
CM S1 0.9897 
  
0.0115 
CM S2 0.9928 
  
0.0192 
CM S3 1.0385 
  
0.0179 
CM L1 1.0176 0.0142 
 
0.0138 
CM L2 0.9335 0.0168 
 
0.0164 
CM L3  1.0124 0.0189 
 
0.0185 
CM L+W1 1.0038 0.0124 0.183 0.0034 
CM L+W2 1.0235 0.0153 0.1855 0.0045 
CM L+W3 1.0171 0.0149 0.1164 0.004 
EC S1 0.1621 
  
0.0112 
   
 
   
 
98
EC S2 0.2182 
  
0.0119 
EC S3 0.0821 
  
0.0054 
EC L1 0.1501 0.0085 
 
0.0082 
EC L2 0.1896 0.0092 
 
0.0088 
EC L3 0.1708 0.0066 
 
0.0065 
EC L+W1 0.0864 0.005 0.0672 0.0015 
EC L+W2 0.1192 0.0072 0.1016 0.0022 
EC L+W3 0.1415 0.0098 0.1358 0.0041 
M S1 1.0061 
  
0.0074 
M S2 0.9888 
  
0.0069 
M S3 0.9745 
  
0.0074 
M L1 0.9366 0.0065 
 
0.0062 
M L2 0.9684 0.0072 
 
0.0067 
M L3 0.9962 0.007 
 
0.0067 
M L+W1 1.0718 0.0074 0.1947 0.0007 
M L+W2 0.5955 0.0045 0.1008 0.0004 
M L+W3 0.9388 0.0068 0.1715 0.0006 
 
A.1.2b UPLC Data (Loading and Processing Experiments) 
 
Table A12: Processing Paclitaxel Retention 
Sample Retention Time 
(minutes) 
Area Concentration 
PTX (mg/L) 
PTX 0 S1 3.107 2010170 9.237234395 
PTX 0 S2 3.101 2004648 9.211859422 
PTX 0 S3 3.101 1376340 6.324626866 
PTX 0 L1 3.101 2055659 9.446267738 
PTX 0 L2 3.1 1991310 9.150567973 
PTX 0 L3 3.098 2064658 9.487620396 
PTX 0 L+W1 3.092 687656 3.159951474 
PTX 0 L+W2 3.091 360123 1.654855342 
PTX 0 L+W3 3.089 515859 2.37050125 
PTX 2 S1 3.094 1793370 8.240984119 
PTX 2 S2 3.096 1890110 8.685528638 
PTX 2 S3 3.098 1942491 8.926232446 
PTX 2 L1 3.097 1976662 9.083256746 
PTX 2 L2 3.039 1921110 8.827981398 
PTX 2 L3 3.094 1852639 8.513340012 
PTX 2 L+W1 3.086 336858 1.547946842 
PTX 2 L+W2 3.084 572074 2.628823248 
PTX 2 L+W3 3.084 226758 1.042009779 
CM S1 3.089 30166 0.138620322 
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CM S2 3.087 29508 0.135596647 
CM S3 3.089 32343 0.148624182 
CM L1 3.089 31706 0.145697008 
CM L2 3.089 40751 0.187261047 
CM L3  3.087 41032 0.188552312 
CM L+W1 3.086 39046 0.179426145 
CM L+W2 3.085 33182 0.152479597 
CM L+W3 3.081 29782 0.136855746 
EC S1 3.094 71426 0.328220351 
EC S2 3.079 48180 0.221399162 
EC S3 3.089 36871 0.169431476 
EC L1 3.08 49284 0.226472318 
EC L2 3.081 41213 0.189384053 
EC L3 3.078 28970 0.133124403 
EC L+W1 3.074 19108 0.087806044 
EC L+W2 3.075 13510 0.062081832 
EC L+W3 3.074 32914 0.15124807 
M S1 3.082 21599 0.099252812 
M S2 3.08 20320 0.093375487 
M S3 3.073 22634 0.104008896 
M L1 3.073 11548 0.053065951 
M L2 3.073 17704 0.081354312 
M L3 3.071 22170 0.1018767 
M L+W1 3.068 27586 0.126764576 
M L+W2 3.071 14086 0.064728696 
M L+W3 3.07 19605 0.090089883 
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A.2 Chapter 4 Data 
A.2.1 PicoGreen 
Where: 
Values of wells read fluorescence  
Sample numbers indicate separate biological samples 
Well numbers indicate duplicates of the same biological sample in separate wells 
T values indicate the number of times the well was read by the plate reader  
 
A.2.1a DNA Release 
 
Table A13: Determining DNA release protocol standard curve. Where standard indicates the 
concentration of DNA in µg/mL. The standard curve was found to be: [fluorescence = 
75890*(DNA concentration) + 6858.1] with an R-squared value of 0.9836. 
Standard 3.556 1.183 0.394 0.131 0.044 0.015 0.0049 0 
Well 1 T1 103350 84084 34569 21691 10225 5907 3792 3786 
Well 1 T2 103989 84079 34513 20406 9218 5468 3676 3567 
Well 1 T3 103829 84386 33528 19849 8898 5584 3495 3552 
Well 2 T1 117392 104652 57754 23222 10278 5785 5082 4247 
Well 2 T2 125078 103599 53422 21204 9616 5809 4657 4058 
Well 2 T3 126514 101450 51992 20524 9211 5637 4610 3772 
Average 113359 93708 44296 21149 9574 5698 4219 3830 
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Table A14: Determining DNA release protocol florescence readings.  
Sample PBS 1 PBS 2 PBS 3 Lysis 1 Lysis 2 Lysis 3 
Well 1 T1 23770 35385 20962 9347 9415 11068 
Well 1 T2 20874 33680 22243 8963 7289 10775 
Well 1 T2 19788 36774 23432 7489 8222 10776 
Well 2 T1 24121 33484 21084 9320 9389 10913 
Well 2 T2 20975 32028 21992 8971 7569 10587 
Well 2 T3 19650 34690 23176 7348 8332 10593 
Well 3 T1 23730 31893 21372 9320 9467 11132 
Well 3 T2 21101 31031 21900 8971 7273 10657 
Well 3 T3 19992 34152 22969 7348 8089 10778 
Average 
Fluorescence 
21555.67 33679.67 22125.56 8564.111 8338.333 10808.78 
DNA Conc. 
(µg/µL) 
0.193669 0.353427 0.201179 0.02248 0.019505 0.052058 
DNA Amount 0.077468 0.141371 0.080472 0.008992 0.007802 0.020823 
 
Table A15: Determining DNA release protocol florescence readings, continued. *Data excluded 
from further computations due to readings outside of the standard curve range.  
Sample Cellulase 
1 
Cellulase 
2 
Cellulase 
3 
Hemi. 1 Hemi. 2 Hemi. 3* 
Well 1 T1 11137 10360 9910 10705 8882 6649 
Well 1 T2 12715 12590 10626 10399 10943 6545 
Well 1 T2 13007 10407 11300 13674 9205 6622 
Well 2 T1 10664 10482 10113 10676 8869 6663 
Well 2 T2 12462 12447 10257 10220 11004 6652 
Well 2 T3 12861 10682 11058 13455 9351 6351 
Well 3 T1 10174 10490 9797 10786 8942 6571 
Well 3 T2 12676 12945 10353 10648 11084 6650 
Well 3 T3 12752 10724 11030 13726 9603 6403 
Average 
Fluorescence 
12049.78 11236.33 10493.78 11587.67 9764.778 6567.333 
DNA Conc. 
(µg/µL) 
0.068411 0.057692 0.047907 0.062321 0.038301 -0.00383* 
DNA Amount 0.034205 0.028846 0.023954 0.031161 0.019151 -0.00192* 
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Table A16: Determining DNA release protocol florescence readings, continued 
Sample Macero. 
1 
Macero. 
2 
Macero. 
3 
Well 1 T1 9453 9950 8849 
Well 1 T2 10547 8854 10100 
Well 1 T2 8656 10651 8571 
Well 2 T1 9491 9841 9850 
Well 2 T2 10230 9016 8622 
Well 2 T3 8378 10730 10055 
Well 3 T1 9080 9898 
 
Well 3 T2 10377 9134 
 
Well 3 T3 8557 10817 
 
Average 
Fluorescence 
9418.778 9876.778 9341.167 
DNA Conc. µg/µL 0.033742 0.039777 0.032719 
DNA Amount 0.016871 0.019889 0.01636 
 
A.2.1b DNase Treatment 
Table A17: Fluorescence readings from PicoGreen Assay used to develop standard curve of DNA 
used for comparison of lyophilized versus DNase+ versus DNase-.  
Standard Curve: Flour = 39767*(Conc.) + 5286.1        R Squared = 9987 
DNA Conc. 
Reading 1 Reading 2 Reading 3 
Average 
(µg/mL) Reading 1-3 
0 7241 7923 7982 7715 
0.0049 4914 5045 4933 4964 
0.015 6337 6268 6552 6386 
0.044 6350 6237 6327 6305 
0.131 12692 12916 11619 12409 
0.394 19093 19044 18840 18992 
1.183 49988 49578 49379 49648 
3.556 147242 148086 147908 147745 
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Table A18: Fluorescence readings for PicoGreen Assay of lyophilized versus DNase+ versus 
DNase- treatments.  
 Reading Reading Reading Avg. Read Avg. DNA Avg. DNA 
 1 2 3 1-3 (µg/mL) (µg/mL) 
Lyophilized 
Sample 1 91001 91305 91610 91305 2.16308078  
Sample 2 77335 78752 79497 78528 1.84177584 2.095118 
Sample 3 94574 96092 97258 95975 2.28049807  
DNase- 
Sample 1 58692 58948 58993 58878 1.34763917  
Sample 2 56324 54011 53483 54606 1.24022179 1.454679 
Sample 3 76755 75519 75484 75919 1.77617707  
DNase+ 
Sample 1 22500 22245 21915 22220 0.42582795  
Sample 2 11609 11485 11031 11375 0.15311439 0.37045 
Sample 3 27027 26306 26042 26458 0.53240711  
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A.2.2 Flavonoid 
A.2.2a Lyophilization and Wash Effect 
 
Table A19: Data showing flavonoid assay data (absorbance (Abs.) and concentration (Conc.). 
Treatments included total culture samples preceding lyophilization, lyophilized samples, and 
samples that were lyophilized then washed. Performed on 2/27/2019 
Standard curve: Abs. = 1.812*(Conc.) + 0.209          (R Squared: 0.9805) 
Standard (mg/mL) 0.000 0.100 0.200 0.400 0.600 0.800 1.000 
Absorbance 0.163 0.315 0.471 0.735 1.099 1.258 1.394 
 
Cell Type: Elicited and Treated with PTX 
Treatment Total Culture Lyophilized Lyophilized & Washed 
Sample 1 Absorbance 1.865 0.829 
 
Sample 2 Absorbance 1.707 0.818 0.288 
Sample 3 Absorbance 1.724 0.744 0.299 
Sample 1 Concentration 0.913907 0.342163 
 
Sample 2 Concentration 0.826711 0.336093 0.043598 
Sample 3 Concentration 0.836093 0.295254 0.049669     
Cell Type: Unelicited 
Treatment  Total Culture Lyophilized Lyophilized & Washed 
Sample 1 Absorbance 1.5700 0.8010 0.1990 
Sample 2 Absorbance 1.3300 0.6460 0.1560 
Sample 3 Absorbance 1.3340 0.8140 0.2450 
Sample 1 Concentration 0.7511 0.3267 -0.00552* 
Sample 2 Concentration 0.6187 0.2412 -0.02925* 
Sample 3 Concentration 0.6209 0.3339 0.0199 
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A.2.2b DNase Effect 
 
Table A20: Data showing flavonoid assay data (absorbance (Abs.) and concentration (Conc.). 
Treatments included lyophilized samples, DNase+ treated samples and DNase- treated samples. 
Performed on 3/19/2019. 
Standard Curve: Abs. = 1.0554*(Conc.) + 0.1816   (R Squared = 0.9977) 
Standard (mg/mL) 0 0.1 0.2 0.4 0.6 0.8 1 
Absorbance 0.158 0.316 0.389 0.619 0.799 1.015 1.247 
 
Absorbance Concentration Avg. Conc. 
 (mg/mL) (mg/mL) 
DNase+ 
0.272 0.085655 0.001327 
0.178 -0.00341  
0.099 -0.07826  
DNase- 
0.392 0.199356 0.118502 
0.271 0.084707  
0.257 0.071442  
Lyophilized 
0.687 0.478871 0.464658 
0.699 0.490241  
0.63 0.424863  
 
A.2.3 Phenolic 
A.2.3a Lyophilization and Wash Effect 
 
Table A21: Data showing phenolic assay data (absorbance (Abs.) and concentration (Conc.) for 
cells. Treatments included total culture samples preceding lyophilization, lyophilized samples, and 
samples that were lyophilized then washed. Performed on 2/27/2019 
Standard Curve: Abs. = 5.3042*(Conc.) + 0.0856   (R Squared: 0.9937) 
Standard 
(mg/mL) 0.000 0.200 0.150 0.100 0.075 0.050 0.025 
Absorbance 0.070 1.112 0.916 0.603 0.531 0.347 0.203 
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Cell Type: Elicited and Treated with PTX 
Treatment Total Culture Lyophilized Lyophilized & Washed 
Sample 1 Absorbance 1.324 0.510 0.106 
Sample 2 Absorbance 1.121 0.562 0.097 
Sample 3 Absorbance 1.317 0.480 0.116 
Sample 1 Concentration 1.167 0.400 0.019 
Sample 2 Concentration 0.976 0.449 0.011 
Sample 3 Concentration 1.161 0.372 0.029     
Cell Type: Unelicited 
Treatment Total Culture Lyophilized Lyophilized & Washed 
Sample 1 Absorbance 0.998 0.990 0.075 
Sample 2 Absorbance 0.976 0.587 0.090 
Sample 3 Absorbance 1.177 0.642 0.103 
Sample 1 Concentration 0.860 
  
Sample 2 Concentration 0.839 0.473 0.004 
Sample 3 Concentration 1.029 0.524 0.016 
 
A.2.3b DNase Effect 
 
Table A22: Data showing phenolic assay data (absorbance (Abs.) and concentration (Conc.). 
Treatments included lyophilized samples, DNase+ treated samples and DNase- treated samples. 
Performed on 3/19/2019. 
Standard Curve: Abs. = 5.0667*(Conc.) + 0.1036   (R Squared = 0.9862) 
Standard (mg/mL) 0 0.025 0.05 0.075 0.1 0.15 0.2 
Absorbance 0.057 0.214 0.399 0.535 0.634 0.806 1.121 
 
Absorbance Concentration Avg. Conc. 
 (mg/mL) (mg/mL) 
DNase+  
0.08 -0.02328  
0.072 -0.03118 -0.0295 
0.069 -0.03414  
DNase- 
0.077 -0.02624  
0.069 -0.03414 -0.0269 
0.083 -0.02032  
Lyophilized 
0.452 0.343746  
0.775 0.662431 0.5598 
0.786 0.673284  
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A.2.4 UPLC 
 
Table A23: UPLC standard curve made for decellularization. Standard runs 1 and 2 were averaged 
to develop a standard curve, and the y-intercept was set to zero.  
Standard Curve: Area = 28010*Conc. 
Standard 
Run 
Number 
Standard 
Concentration 
(mg/L) 
Retention 
Time 
(Minutes) 
 
Area 
1 6.25 2.959 191008 
1 12.5 2.941 322323 
1 25 2.94 696187 
1 50 2.942 1434778 
2 6.25 2.966 179350 
2 12.5 2.982 316460 
2 25 2.985 677031 
2 50 2.988 1392753 
  
Table A24: UPLC data for paclitaxel retention through decellularization process in samples treated 
with DNase, samples treated with buffer only, and lyophilized cells only.  
Treatment Sample Ret. Time PTX Conc. 
Number (mins) Area mg/L 
DNase+  
Biomass 1 2.948 158351 0.707 
Biomass 2 2.956 157802 0.704 
Biomass 3 2.952 144573 0.645 
Supernatant 1 2.952 517184 2.308 
Supernatant 2 2.959 503952 2.249 
Supernatant 3 2.966 607290 2.710 
DNase-  
Biomass 1 2.967 155209 0.693 
Biomass 2 2.966 195529 0.873 
Biomass 3 2.97 147898 0.660 
Supernatant 1 2.973 434382 1.939 
Supernatant 2 2.975 580060 2.589 
Supernatant 3 2.974 495015 2.209 
Untreated  
Lyoph. 1 2.981 1497062 6.681 
Lyoph. 2 2.981 1244450 5.554 
Lyoph. 3 2.983 1450753 6.474 
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A.3 Chapter 5 Data 
A.3.1 Biomass Release Experiment 
A.3.1a UPLC Data (Biomass Release) 
 
Table A25: UPLC standard curve made for release studies. Standard runs were averaged to develop 
a standard curve, and the y-intercept was set to zero.  
Standard Curve: Area = 17206*(PTX Conc.) 
Run 
PTX Standard 
Concentration 
Retention 
Time Area 
Number (mg/L) (mins)  
1 50 3 919515 
2 50 3.008 901975 
3 50 3.005 795590 
1 25 3.001 476498 
2 25 3.003 471127 
3 25 3.006 464069 
1 12.5 3.001 123410 
2 12.5 3.004 124360 
1 6.25 3.001 31848 
2 6.25 3.006 31190 
 
Table A26: UPLC Data for PTX release from decellularized biomass. Where PTX concentration 
was determined from the UPLC standard curve, then PTX (mg/sample) was corrected to the volume 
of the sample taken. 
Sample Sample Hour Retention Time Area PTX Conc. PTX 
Type Number  (mins)  (mg/L) mg/sample 
Su
pe
rn
at
an
t (
85
0 
uL
) 
1 1 2.999 84788 0.615976985 0.000724679 
2 1 2.993 72912 0.529698942 0.000623175 
3 1 2.995 91665 0.665937754 0.000783456 
1 6 2.998 34120 0.247878647 0.000291622 
2 6 2.998 30206 0.219443799 0.000258169 
3 6 2.999 43479 0.315870917 0.000371613 
1 12 2.997 10768 0.078228525 9.20336E-05 
2 12 2.996 13789 0.100175811 0.000117854 
3 12 2.999 17401 0.126416657 0.000148725 
1 24 3 4340 0.031529699 3.70938E-05 
2 24 3 4714 0.034246774 4.02903E-05 
3 24 2.998 6124 0.044490294 5.23415E-05 
1 48 3.001 1342 0.009749506 1.147E-05 
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2 48 2.998 1735 0.012604615 1.4829E-05 
3 48 2.995 2139 0.015539637 1.82819E-05 
1 72 2.996 157 0.00114059 1.34187E-06 
2 72 3 547 0.003973904 4.67518E-06 
3 72 2.996 842 0.006117052 7.19653E-06 
1 144 0 0 0 0 
2 144 0 0 0 0 
3 144 0 0 0 0 
1 192 0 0 0 0 
2 192 0 0 0 0 
3 192 0 0 0 0 
1 240 2.998 90023 0.654008776 0.000769422 
2 240 2.998 1371 0.009960188 1.17179E-05 
3 240 2.996 269 0.00195426 2.29913E-06 
Biomass 
Remainder 
1 - 3 636 0.004620481 4.62048E-06 
2 - 3.002 314 0.002281181 2.28118E-06 
3 - 2.995 600 0.004358945 4.35894E-06 
 
A.3.1b Sample Release Analysis 
 
Table A27: Sample analysis of release profile development for biomass into BSA (mass of PTX 
released in mg). Hour 1 samples are directly from UPLC data, converted to mg/mL. Following time 
points were calculated by subtracting the mass of PTX left over from the previous sample (Hour 1, 
where 0.85 mL was sampled, 0.15 mL remained) from the concentration measured at that time 
point. 
 Sample Number Average Standard 
Hour 1 2 3 (1-3) Deviation 
1 0.000615977 0.000529699 0.000665938 0.000603871 6.89214E-05 
6 0.000155482 0.000139989 0.00021598 0.000170484 4.01554E-05 
12 2.90868E-09 6.72592E-05 7.9036E-05 4.87661E-05 4.26387E-05 
24 1.97954E-05 1.92204E-05 2.55278E-05 2.15145E-05 3.48745E-06 
48 5.02005E-06 7.4676E-06 8.86609E-06 7.11791E-06 1.94672E-06 
72 0 2.08321E-06 3.78611E-06 1.95644E-06 1.89623E-06 
144 0 0 0 0 0 
192 0 0 0 0 0 
240 0 9.96019E-06 1.95426E-06 3.97148E-06 5.27762E-06 
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A.3.2 Alginate Release Experiment  
 
Table A28: UPLC Data for PTX release from decellularized biomass and free PTX from alginate 
microbeads. Where PTX concentration was determined from the same UPLC standard curve as the 
biomass release experiment, then PTX (mg/sample) was corrected to the volume of the sample 
taken.  
Sample Hour Ret. Time Area PTX Conc. PTX 
Number  (mins)  (mg/L) mg/sample 
Biomass 1 1 2.998 63577 0.46188103 0.001358474 
Biomass 2 1 2.997 60789 0.441626468 0.001298901 
Biomass 3 1 3.001 63162 0.458866093 0.001349606 
Biomass 1 6 3.002 40902 0.29714925 0.000873968 
Biomass 2 6 3.001 38525 0.279880565 0.000823178 
Biomass 3 6 2.999 34969 0.254046554 0.000747196 
Biomass 1 12 3 14386 0.104512961 0.000307391 
Biomass 2 12 3.004 9754 0.070861909 0.000208417 
Biomass 3 12 2.999 15297 0.111131291 0.000326857 
Free PTX 1 1 3.001 24752 0.179820993 0.000528885 
Free PTX 2 1 3 20979 0.152410496 0.000448266 
Free PTX 3 1 3.002 19739 0.143402011 0.000421771 
Free PTX 1 6 3.001 15491 0.112540683 0.000331002 
Free PTX 2 6 2.999 14556 0.105747995 0.000311024 
Free PTX 3 6 2.999 2135 0.015510578 4.56193E-05 
Free PTX 1 12 3.001 403 0.002927758 8.61105E-06 
Free PTX 2 12 3 1834 0.013323841 3.91878E-05 
Free PTX 3 12 3 738 0.005361502 1.57691E-05 
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Appendix B. Program Protocols 
B.1 PicoGreen 
 
Protocol description 
Protocol name ..................... PicoGreen_JMC 
Protocol number ................... N/A 
Name of the plate type ............ NUNC 96 Well Black 265301 
Number of wells in the plate ...... 8 X 12 
Height of the plate ............... 15.0 mm 
Offset of the wells ............... 10.885 mm, 14.753 mm 
Distance between wells ............ 8.994 mm, 8.980 mm 
Number of repeats ................. 3 
Delay between repeats ............. 0 s 
Measurement height ................ 18.00 mm 
Protocol notes ....................  
Shaking duration .................. 5.0 s 
Shaking speed ..................... Fast 
Shaking diameter .................. 0.10 mm 
Shaking type ...................... Linear 
Repeated operation ................ Yes 
Name of the label ................. PicoGreen_JMC 
Label technology .................. Prompt fluorometry 
CW-lamp filter name ............... F485 
CW-lamp filter slot ............... A5 
Emission filter name .............. F535 
Emission filter slot .............. A5 
Measurement time .................. 0.1 s 
Emission aperture ................. Normal 
CW-lamp energy .................... 65535 
Second measurement CW-lamp energy . 0 
Emission side ..................... Above 
CW-Lamp Control ................... Stabilized Energy 
Excitation Aperture ............... N/A 
Plate map of plate 1: Varies with trial  
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A | M   M   M   M   M   M   M   M   M   M   M   M    
B | M   M   M   M   M   M   M   M   M   M   M   M    
C | M   M   M   M   M   M   M   M   M   M   M   M    
D | M   M   M   M   M   M   M   M   M   M   M   M    
E | M   M   M   M   M   M   M   M   M   M   M   M    
F | M   M   M   M   M   M   M   M   M   M   M   M    
G | M   M   M   M   M   M   M   M   M   M   M   M    
H | M   M   M   M   M   M   M   M   M   M   M   M    
Protocol created by ...............  
Protocol creation date ............ 7/13/2017 
Protocol last edited by ........... awerner 
Protocol last edited .............. 1/25/2019 
Instrument serial number: ......... 7895 
Assay ID:  ........................ 19266 
Measured on ....................... 1/25/2019 2:18:18 PM 
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Appendix C. Product Information 
C.1 Cell Lines 
Taxus chinensis: 21260C 
Taxus cuspidata: 48-82-A 
 
C.2 Chemicals and Reagents 
Sucrose (Caisson Laboratories, Smithfield UT) 
Gamborg-B5 (PhytoTechnology Laboratories, Lenexa KS) 
Benzyl adenine (Sigma-Aldrich, St. Louis MO) 
1-napthalenacetic acid (Sigma-Aldrich, St. Louis MO) 
Ascorbic acid (Fisher Scientific, Hampton NH) 
Citric acid (PhytoTechnology Laboratories, Lenexa KS) 
L-glutamine (Caisson Laboratories, Smithfield UT) 
MeJA: methyl jasmonate (Sigma-Aldrich, St Louis MO, 392707) 
Cyclosporine A (Cayman Chemical, Ann Arbor MI, 12088) 
Verapamil: (+ -) - verapamil hydrochloride (Acros Organics, Geel (Belgium), 329330010) 
Vanadate: sodium orthovanadate (MP Biomedicals, Solon OH, 218058) 
Glycerol (Thermo Fischer Scientific, Waltham MA, A16205-0D) 
Sodium chloride (Sigma-Aldrich, St Louis MO, S5886) 
Sodium azide (Acros, New Jersey, 19038-1000) 
Hemicellulase (Sigma-Aldrich, St Louis MO, H-2125) 
Cellulase (bioWORLD, New York NY 21500003-1) 
Macerozyme (ICN Biomedicals Inc, Aurora OH, 152340) 
Triton X-100 (Laboratory Grade, Sigma-Aldrich, St Louis MO, 9002-93-1) 
PBS: phosphate buffered saline (Fisher Scientific, Hampton NH, BP2944-100) 
DNase: Deoxyribonuclease I from bovine pancreas, 2000 units/mg (Sigma-Aldrich, St. Louis 
MO, D5025) 
DPBS: Dulbecco’s PBS (DPBS) (Thermo Fisher Scientific, Waltham MA, 14080-055) 
Paclitaxel (Alfa Aesar, Ward Hill, MA) 
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Quant-iTTM PicoGreenTM dsDNA Assay Kit (Thermo Fisher Scientific, Waltham MA, P11496) 
Sodium carbonate (Fischer Scientific, Hampton NH, S263-500) 
Sodium nitrite (Acros, New Jersey, 42435-5000) 
Aluminum chloride (Sigma-Aldrich, St Louis MO, 7784-13-6) 
Sodium hydroxide (Sigma-Aldrich, St Louis MO, 1310-73-2) 
Catechin: (+)- catechin (hydrate) (Cayman Chemical, Ann Arbor MI, 70940) 
Hoechst Stain (Hoechst 33342, Tocris Bioscience, Bristol United Kingdom, 5517) 
Paraformaldehyde (PFA) (Acros, New Jersey, 30525-89-4) 
Bovine serum albumin (BSA) (Sigma-Aldrich, St Louis MO, 9048-46-8) 
Sodium alginate (Willpowder, Miami Beach FL) 
Calcium chloride (CaCl2) (Willpowder, Miami Beach FL) 
 
C.3 Instruments and Products 
Shelf lyophilizer (VirTis BenchTop Pro with Omnitonics, SP Scientific, Stone Ridge, NY) 
Evaporative centrifuge (Vacufuge plus, Eppendorf, Hamburg Germany) 
Sonicator (Aquasonic 75HT, VWR, Radnor PA) 
Coulter Counter: Multisizer 3TM Coulter Counter (Beckman, Brea CA) 
0.5 mm diameter zirconium silicate beads (Next Advance, Troy NY) 
Bullet Blender (Next Advance, Troy NY) Model: 24 Gold 
Mechanical homogenizer: (BioSpec Products, Inc., Bartlesville OK, Tissue TearorTM) 
UPLC: (Waters, Milford MA, Acquity UPLC H-Class)  
Fluorescent Plate Reader: Victor3 1420 Multilabel Plate Reader (PerkinElmer, Waltham, MA) 
Colorimetric Plate Reader: (Accuskan Go, Fisher Scientific, Hampton NH) 
Microscope: Nikon Eclipse E600 MVI, Avon MA 
Shaker (New Brunswick Scientific Co. Inc, Edison NJ, Model G24) 
Centrifuge: (Eppendorf, Hamburg Germany, Model 5418R)  
 New	Brunswick	Scientific	Co.	Inc,	Edison	NJ,	G24	Environmental	Incubator	Shak 
 
